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Specific and efficient targeting to tumors as well as many other diseases is a key to 
the success in several therapeutic interventions. The specificity offers the ideal way to 
transport and deliver a variety of biomedical entities for diagnosis, prevention, and treatment, 
selectively to the targeted sites. These specific targeting and delivery potentially lead to the 
advancement of noninvasive diagnostics and provide safer therapeutic options. Numerous 
factors can effectuate and determine the accomplishment of the site-specific targeting. In this 
dissertation, I have comprehensively investigated the influence of size and specificity on 
pharmacokinetics, biodistribution and tumor targeting of commonly used biologics. Six 
different fluorescently-labeled biologics, including two antibodies, two antibody fragments, 
serum albumin, and streptavidin, were used in the study to examine their distribution at 
whole body, ex-vivo tissue, and cellular levels in mice bearing human cervical cancer cells. 
The understanding of these pharmacokinetic parameters and tumor targeting outcomes would 
assist not only in future molecular imaging design but also therapeutic intervention 
development. Thereby it could render opportunity for novel treatment regimens. 
Utilizing the fundamental understanding in pharmacokinetics and biodistribution 
from our study, we have engineered two different targeted delivery systems for both imaging 
and delivery applications. The first system is super paramagnetic iron oxide (SPIO) 
nanoparticle for magnetic resonance imaging (MRI) application. The second system is 
polyplex nanoparticle for large genetic content delivery. Among a wide range of targeting 
molecules, intercellular adhesion molecule (ICAM)-1 is of great interest as a versatile 
targeting molecule due to its constitutively over-expressed in many carcinomas including 
breast, colon, non-small cell lung, and gastric tumors compared to corresponding normal 
epithelial cells, in tumor vasculature within an inflammatory network, and in inflammation 
sites. Targeting ICAM-1 would offer a great benefit through combinatorial targeting 
strategies to both tumor cells and tumor-associated endothelial cells. Validated in in vivo 
mouse models, our targeted delivery systems localized preferentially to the tumors, inflamed 
vasculature, as well as systemic and subcutaneous inflammation. The studies presented here 
demonstrate a comprehensive understanding of size and specificity parameters to tumor 
targeting outcomes, along with two examples of targeted delivery systems for imaging and 
therapeutic implications. We anticipate this work may greatly contribute to successful 
translation of the molecular imaging and therapeutic delivery systems into the clinic. 
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CHAPTER 1 
 
INTRODUCTION 
 
Inflammation, cancer, and cancer metastasis 
 
Cancer results from the outgrowth of a clonal population of cells in tissues. Central to 
the development of cancer, referred to as carcinogenesis, are genetic changes that endow 
these “cancer cells” with many of the hallmarks of cancer, including 1) sustaining 
proliferative signaling, 2) evading growth suppressors, 3) resisting cell death, 4) enabling 
replicative immortality, 5) inducing angiogenesis, 6) activating invasion and metastasis, 7) 
reprogramming of energy metabolism, and 8) evading immune destruction [1]. Cancer could 
also be considered as a step-wise development functionally grouped into three phases: 
initiation-genomic changes within the cancer cell, promotion-clonal expansion of the 
initiated cells, and progression-substantial growth in tumor size as well as metastasis [2, 3]. 
However, while the genetic changes that occur within cancer cells themselves, such as 
activated oncogenes or dysfunctional tumor suppressors, together with cell autonomous 
promotion and progression properties are necessary for tumorigenesis, they are not sufficient. 
In fact, several research studies have identified that the neoplastic processes; fostering 
proliferation, survival, and migration require support from tumor microenvironment, which is 
largely orchestrated by inflammatory cells [3, 4]. These inflammatory cells promote early 
neoplastic process by producing an attractive environment for tumor growth, facilitating 
genomic instability, and promoting angiogenesis [3]. They also produce chemokines and 
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cytokines, which regulate the growth, migration, differentiation, and metastasis of neoplastic 
cells [3, 5, 6]. In the late tumorigenic process, neoplastic cells also divert inflammatory 
mechanisms such as selectin–ligand interactions, MMP production, and chemokine functions 
to favor neoplastic spread and metastasis [3].  
 
Cancer targeting strategies 
 
The major requirement for the success in cancer treatment and imaging is that the 
therapeutic/imaging agents must efficiently and selectively reach the targeting cells in vivo in 
optimal quantities with minimal off-targeted cell localization. Over the past century, since 
Paul Ehrlich, considered the “father of chemotherapy”, suggested the concept of a “magic 
bullet”, i.e., “a drug that selectively attaches to diseased cells but is not toxic to healthy cells” 
[7], a great deal of effort has been made for this direction, focusing particularly on cancer 
treatment. To reach cancer cells in a tumor, a therapeutic agent must make its way into the 
chaotic blood vessels of the tumor, across the vessel wall into the interstitium, then transport 
through the interstitial space and lymphatics, and finally bind to cancer cells [8, 9]. 
Moreover, during the journey, the therapeutic molecule may bind nonspecifically to proteins 
or other tissue components, which leads to the rapid clearance and metabolization within 
seconds after i.v. administration [10, 11]. In addition, several other obstacles, as outlined in 
Table 1 [12], still persist and need to be overcome. 
Many different imaging and delivery systems have been innovatively developed over 
the past years to overcome these barriers, and to improve their pharmacokinetic profile and 
their accumulation at the target site. Several strategies have been conceived for nanomedicine 
 3 
directed to putative biological targets including passive drug targeting, active targeting to 
cancer cells, active targeting to endothelial cells, and triggered drug delivery (using stimuli-
responsive carrier materials) [13-16], as shown in Figure 2.  
 
Table 1. Barriers limiting the delivery of i.v. administrated anticancer agents to tumors. 
Note that several barriers are inter-related, and that not all barriers apply to all types of 
(chemo-) therapeutic agents. Table is from the article originally published in [12] 
 
 
 
 
 
 
 
Barriers to drug delivery to tumors   
Anatomical barriers Physiological 
barriers 
Chemical barriers Clinical barriers 
Vascular 
endothelium 
Renal filtration Low solubility  Low efficacy  
Perivascular space Hepatic degradation  Low stability High toxicity 
Cellular membrane High tumor cell 
density 
Low molecular 
weight  
Need for 
hospitalization 
Nuclear membrane High interstitial fluid 
pressure 
Large volume of 
distribution 
Frequent 
administration 
Blood brain barrier Drug efflux pumps Charge interactions Low cost-
effectiveness 
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Figure 1. The transport barriers to tumor-targeted delivery. Therapeutic agents enter a tumor 
through its blood supply. These drugs must then extravasate cross  the microvascular walls to 
penetrate into tissues. The drugs then diffuse through the extravascular space and eventually 
distribute to their target cancer cells. The figure is from the article originally published in [9]. 
In addition to this, a large number of other barriers need to be considered including e.g. 
hepatic and enzymatic degradation, the high interstitial fluid pressure that is typical of 
tumors, cellular and nuclear membranes, and the presence of drug efflux pumps [12]. 
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Figure 2. Strategies used for biomedical entity targeting and localization to tumor cells. (A) 
Passive drug targeting. Circulating nanoparticles passively extravasate in solid tumor tissue, 
by means of the enhanced permeability and retention effect-EPR effect, the property by 
which nanoparticles tend to accumulate in tumor tissue much more than they do in normal 
tissue due to the enhanced permeability of blood vessels, i.e., through the disorganized and 
leaky vasculature surrounding the solid tumor together with the absence of lymphatic 
drainage (a) After distributed through the extracellular matrix, the released drug diffuses into 
the cancer cells. (B) Active targeting to cell surface receptors (over-) expressed by cancer 
cells. Once nanoparticles passively extravasate and concentrate in the target tissue via the 
EPR effect, the presence of ligands grafted onto the nanoparticle surface enable specific 
targeting and, in some cases, enhanced uptake and internalization of the nanoparticles via 
receptor-mediated endocytosis. (b) Tumor-specific ligands on the nanoparticles bind to cell 
surface receptors, concentrating drug to the tumor cell vicinity and, in case of internalization-
prone cell surface receptors, triggering internalization, of the nanoparticles into the cell. The 
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drug is then released from the nanoparticle, due to acidic pH in endosomes, and diffuses into 
cytoplasm. (C) Active targeting to receptors (over-) expressed by endothelial cells. 
Nanoparticles can be targeted to bind to angiogenic endothelial cell surface receptors with 
the aims of: eradicating tumor blood supply to deprive cancer cells of oxygen and nutrients 
(c), and improving drug delivery to tumor cells via the EPR effect with synergistic targeting 
both the vascular tissue and tumor cells. (D) Triggered drug delivery by stimuli-sensitive 
nanomedicines. After passively accumulating at the tumor via EPR or while circulating in the 
tumor vasculature (d), the nanoparticles can be activated, to release their contents, by 
external stimuli, like hyperthermia, light, magnetic fields, ultrasound. Figure 3 (a-d, A-D) are 
reproduced from [17]. 
 
Passive targeting 
The pathophysiological characteristics of solid tumors feature the enhanced 
permeability of tumor blood vessels, in contrast to the vasculature in healthy tissues, and the 
lack of lymphatic drainage. The enhanced permeability in tumor microvasculature is a result 
of poorly differentiated vasculature, abnormal branching and enlarged interendothelial gaps. 
These large gaps, up to ~600 nm in size comparing to ~5 nm in normal vessels [17-19], allow 
for extravasation of nanoparticles into the tumor interstitium. Together with the lack of 
functional lymphatics, the enhanced permeation and retention effect (EPR effect) can be 
exploited as a passive targeting mechanism for drug delivery through selective extravasation 
and accumulation of long-circulating therapeutic agents in the tumor interstitium over time. 
This passive targeting mechanism is arguably the most important strategy for improving the 
delivery. The vast majority of currently approved nanomedicines for tumor targeting in 
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clinics rely heavily on the EPR effect, e.g. Myocet (non-PEGylated liposomal doxorubicin), 
Doxil (PEGylated liposomal doxorubicin), Abraxane (albumin-based pacitaxel) and 
Genexol-PM (paclitaxel-containing polymeric micelles; pre-approved in Korea) [12]. 
Currently several additional passively tumor-targeted nanomedicines are in clinical trials and 
many more in early- and late-stage preclinical development [12, 20]. 
 
Active targeting to cancer cells 
As opposed to passive drug targeting, active drug targeting involves the use of 
targeting ligands to direct the binding of nanomaterials to receptor (over-) expressed at the 
target site [21]. Notably, active drug targeting is generally implemented not to improve 
overall tumor accumulation, as it relies solely on passive distribution via EPR effect, but to 
improve target cell recognition and target cell uptake, which is postulated to improve the 
therapeutic efficacy as compared with nontargeted nanoparticles. While the potential benefit 
of active targeting nanoparticles seems to be widely accepted, to date only antibody-based 
nanomedicines, such as Zevalin, Mylotarg, Ontak and Bexxar have been approved for 
clinical use but none of actively targeted liposomes, polymers, micelles and nanoparticles 
have thus far been approved for clinical use, and only very few are in clinical trials [12]. The 
very reason that actively targeted ‘classical’ nanomedicines, e.g. liposomes, polymers and 
micelles, have thus far largely failed to demonstrate benefit at the (pre-) clinical level is 
mostly attributed to the fact that after leaving the highly leaky tumor vasculature, there are 
quite a number of anatomical and physiological barriers that need to be overcome before 
antibody- or peptide-targeted formulations can bind to (and enter) cancer cells. These include 
the presence of several biological cell barriers between endothelial and tumor cells including 
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pericyte-, smooth muscle cell- and fibroblast-based cell layers, the high cellular density 
within solid malignancies, and the high interstitial fluid pressure that is a typical 
characteristic of tumors [20, 22]. Moreover, the binding-site barrier further limits the 
penetration of actively targeted nanomedicines into the tumor interstitium [23]. Therefore, 
actively targeted nanomedicines potentially tend to have problems finding their target cells, 
and they sometimes fail to demonstrate an advantage over passively targeted formulations. 
 
Active targeting to endothelial cells 
The major shortcoming in both passive and active targeting to tumor cells has been 
identified in several studies over the years [13, 17, 20, 24-27]. It is related to the poor 
penetration of nanomedicines through interstitial and tumor tissue due to a variety of 
biological barriers, including pericyte-based, smooth muscle cell-based, and fibroblast- based 
cell layers between endothelial and cancer cells, as well as a plethora of cellular processes 
and anatomic tumor issues (i.e., the high cellular density within solid tumors, high interstitial 
fluid pressure, and heterogeneous EPR effect dramatically varying from tumor to tumor and 
from patient to patient [20]). To address these issues, a variety of vascular-targeted 
nanoformulations have been designed and evaluated [12, 13, 24, 27]. Example of angiogenic 
endothelium targeting are 1) the antibody fragment L19 against extra-domain B domain of 
the oncofetal protein fibronectin highly up-regulated on angiogenic vasculature, 2) the 
natural sLex ligand binding to E- and P-selectin, inflammation markers [28], 3) the peptide 
termed VP for Vascular cell adhesion protein-1 expressed in inflamed tissue [29, 30] 4) the 
several linear and cyclic derivatives of the oligopeptides containing the Arg-Gly-Asp (RGD) 
sequence, which binds to integrins on angiogenic endothelium [31-33]. Tumor vasculature-
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targeting nanomedicines do not depend on extravasation and penetration across several 
biological cell barriers as well as the high tumor cell density and the high interstitial fluid 
pressure, mentioned earlier, in order to reach the target cancer cells. In addition, they 
recognize their target receptors much more easily and frequently than do cancer cell-targeting 
nanomedicines. Thus, it is anticipated that endothelial cell-targeting nanomedicines could 
offer another highly potential strategy for improving antitumor efficacy [12, 17]. Moreover, 
therapeutic disrupting tumor vasculature does not only deprive tumors of oxygen and 
nutrients but also enhance EPR effect due to increased vasculature leakiness. Along with the 
potential design to release therapeutic contents within the tumor vasculature upon binding, 
enabling low-molecular-weight drugs to penetrate deep into the tumor interstitium, this 
vasculature-targeting nanomedicines can significantly provide extra benefits for therapeutic 
treatment. Furthermore, the recent strategy against cancer is normalizing the tumor 
microenvironment. For instance, vascular normalization, involves correction of excessive 
angiogenesis signaling to repair abnormalities in vascular structure and function [35]. 
Vascular normalizing therapies include anti-angiogenics, reducing interstitial fluid pressure 
[34] and increasing perfusion [36]. Rationally, active targeting to endothelial cell strategies 
can be implemented for the success of vascular normalization leading to improvement of 
nanomedicine supply to tumors as well as increase of their effective permeability [37]. 
Intriguingly, the vasculature normalization may be combined with other conventional 
strategies for a pronounced improvement in nanomedicine delivery, distribution and efficacy. 
 
Triggered drug delivery 
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Another targeting strategy capable of generating innovative nanoformulations focuses 
on the possibility that a nanosystem can be triggered to release their contents upon exposure 
to external stimuli, such as light, heat, ultrasound, and magnetic fields. An example of such 
stimuli-responsive nanomedicines that hold significant clinical potential is Thermodox, a 
temperature-sensitive doxorubicin-PEGylated liposomes. It is designed to release the 
conjugated chemotherapeutic drug only upon applying regionally confined triggers, either 
upon EPR-mediated passive tumor accumulation, or already during circulation, thereby 
maximizing drug release at the pathological site, while preventing damage to potentially 
endangered healthy tissues [38]. Despite the clinical potential of such nanoformulations, 
there are still several important limitations to their rapid clinical development, which include 
manufacturing difficulties and problems with stimuli- responsiveness and the stability of the 
controlled-release nanomaterials [12]. To overcome these shortcomings and to develop more 
effective nanoparticles for triggered drug delivery, more effort is being undertaken, both at 
the academic and at the industrial level. 
 
Commonly used biologics and nanoparticles in cancer therapy 
 
Since the discovery in 1948 that cytotoxic folate antimetabolites could be used in the 
treatment of childhood leukemia, our basic approach to cancer therapy has remained 
fundamentally the same: surgery followed by sublethal administration of various cytotoxic 
compounds or radiation [39]. In many cases, conventional treatments for cancer have clinical 
success, but they also have limitations. Surgery and radiotherapy are effective for the 
treatment of localized tumors, but they may not be useful for disseminated disease or for 
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tumors located in areas that are difficult or dangerous to reach [40]. Traditional 
chemotherapy can be severely toxic to normal tissue and also could not provide enough 
therapeutic doses. It flags the need of new and better treatment regimes utilizing novel 
rationales, methodologies as well as therapeutic modalities. Not until 1982 the first 
biotechnology-derived product (biologic) approved for therapeutic use was biosynthetic 
“human” insulin made by recombinant DNA technology. Since then biologics hold a great 
deal of promise among the therapeutic interventions for a wide range of disorders, including 
cancer and inflammatory diseases. Millions of people worldwide have benefited from 
hundreds biologic products and vaccines available today [41, 42]. Although the first biologic 
was approved in the early 1980s, the use of these agents in the treatment of cancer is still 
relatively new [43].  
Biologics differ from traditional pharmaceutical drugs. They are typically larger and 
more complex molecules than chemical drugs. Biologics include: (1) naturally occurring or 
modified biologic compounds such as vaccines, hormone extracts, and blood products; (2) 
recombinant proteins or peptides; (3) monoclonal antibodies and fusion proteins; and (4) 
antisense oligonucleotides to nucleic acids [44].  Among a wide range of biologic products, 
albumin is of great interest as a versatile protein carrier for drug targeting and for improving 
the pharmacokinetic profile of peptide- or protein-based drugs. Albumin is the most abundant 
plasma protein (35–50 g/L human serum) with a molecular weight of 66.5 kDa. Albumin 
exhibits very long half-life, extremely robust: it is stable in the pH range of 4–9, soluble in 
40% ethanol, and can be heated at 60 °C for up to 10 h without deleterious effects. These 
properties as well as its preferential accumulation in solid tumors [45-48] and inflamed tissue 
[49-51], its ready availability, its biodegradability, and its lack of toxicity and 
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immunogenicity make it an ideal candidate for drug delivery. Clinically, a methotrexate-
albumin conjugate, an albumin-binding prodrug of doxorubicin, i.e. the (6-maleimido) 
caproylhydrazone derivative of doxorubicin (DOXO-EMCH), and an albumin paclitaxel 
nanoparticle (Abraxane) have been evaluated clinically. Several albumin-based market 
products have been approved Levemir® and Victoza® (antidiabetic product), Abraxane® 
(anti non-small cell lung cancer, breast cancer and metastatic pancreatic cancer product) [52], 
and Nanocoll® and Albures® (for lymphoscintigraphy and diagnosis of cancer and 
rheumatoid arthritis) [53]. Along with albumin, streptavin is playing an increasing role as a 
drug carrier in the clinical setting [54-58] due to its comparable benefit properties to albumin 
plus its uniquely ultra-high affinity to biotin characteristic. This characteristic offers 
markedly convenience for further carrier modification (e.g. drug, peptide, protein, nucleic 
acid-conjugation), as it does not require any conjugation chemistry. Recently over the past 
years since the first FDA-approved therapeutic monoclonal antibody in 1986 for transplant 
rejection prevention [59, 60] and in 1997 the first antibody for cancer treatment was 
approved [59], monoclonal antibodies have entered the mainstream of cancer therapy. Their 
first use was as antagonists of oncogenic receptor tyrosine kinases, but today monoclonal 
antibodies have emerged as long-sought vehicles for the targeted delivery of potent 
chemotherapeutic agents and as powerful tools to manipulate anticancer immune 
responses[39]. In 2007, eight of the 20 best-selling biotechnology drugs in the U.S. are 
therapeutic monoclonal antibodies [61].  Currently, there are 13 antibodies approved by the 
FDA for various oncology indications, and many more are currently being evaluated in 
clinical trials [39]. Antibodies may be used in their native state or as fragments. Commonly 
well established antibody fragments include antigen-binding fragments (Fab), dimers of 
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antigen-binding fragments ((Fab′)2), and single-chain fragment variables (scFv). There are, 
as well, several engineered fragments that would require further gene modification or 
conjugation procedures, e.g., scFv-crystallizable fragment (Fc), diabody, triabody. 
In addition to antibodies, aptamers, which are short single-stranded DNA or RNA, are 
another promising targeting agent and currently are in active research studies. As an example 
of aptamer use, docetaxel (Dtxl)-encapsulated nanoparticles are surfacely modified with a 
targeting aptamer to the antigen on the surface of prostate cancer cells. The system 
demonstrated high selectivity and efficacy in vivo [62]. Growth factor or vitamin interactions 
with cancer cells also offering additional strategy to target cancer cells. Epidermal growth 
factor (EGF) and vitamin folic acid (folate) are examples of growth factor and vitamin that 
have been used for cancer targeting [63].  
While, biologics have widely been accepted for cancer treatment, a new strategy 
emerges hoping for improving therapeutic efficiency. This strategy utilizes a wide range of 
engineered materials and formulations to generate sophisticated nanoscaffolds for drug 
delivery. Generally these nanocarriers are in the size of 1–100 nm in diameter. They 
generally offer abilities to carry multiple drugs and/or imaging agents and to release drugs in 
controllable or triggerable manner. The current nanocarriers used as drug delivery vectors 
include polymer conjugates, polymeric nanoparticles, lipid-based carriers such as liposomes 
and micelles, dendrimers, carbon nanotubes, silica oxides, metal oxides, quantum dots and 
gold nanoparticles. These nanocarriers have been explored for a variety of applications such 
as drug delivery, imaging, photothermal ablation of tumours, radiation sensitizers, detection 
of apoptosis, and sentinel lymphnode mapping [17, 64-67]. Although these materials are 
likely to provide several advantages, their utilization in biomedicine is, to certain extent, 
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limited. To translate the developed nanomedicines into clinical practice successfully, several 
issues still needed to be addressed, including a favorable blood half- life and physiologic 
behavior with minimal off-target effects, effective clearance from the human organism, 
minimal or no toxicity to healthy tissues in living organisms, potentials to commercially 
scale-up [12, 63, 68]. 
 
 
 
Figure 3. Examples of nanocarriers for targeting cancer. A wide range of nanomaterials can 
be implemented for cancer intervention. However, the three main components, a carrier, a 
targeting moiety, and a cargo, e.g. therapeutic drugs, are generally preserved. Figure 
reproduced from [63]. 
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Table 2. Representative examples of nanocarrier-based drugs on the market. Table 
reproduced from [63] 
Representative examples of nanocarrier-based drugs on the market 
Compound Commercial name Nanocarrier Indications 
Styrene maleic 
anhydride-
neocarzinostatin 
(SManCS) 
Zinostatin/Stimalm
er 
Polymer–protein 
conjugate 
Hepatocellular 
carcinoma 
Peg-l-asparaginase Oncaspar Polymer–protein 
conjugate 
Acute lymphoblastic 
leukemia 
Peg-granulocyte 
colony-stimulating 
factor (g-CSf) 
 
Neulasta/Pegfilgras
tim 
Polymer–protein 
conjugate 
Prevention of 
chemotherapy-
associated neutropenia 
IL2 fused to 
diphtheria toxin 
 
Ontak (Denilelukin 
diftitox) 
Immunotoxin 
(fusion protein) 
Cutaneous t-cell 
lymphoma 
Anti-CD33 antibody 
conjugated to 
calicheamicin 
Mylotarg Chemo-
immunoconjugate 
Acute myelogenous 
leukemia 
Anti-CD20 
conjugated to 
yttrium-90 or 
indium-111 
Zevalin Radio-
immunoconjugate 
Relapsed or refractory, 
low-grade, follicular, or 
transformed non-
Hodgkin’s lymphoma 
Anti-CD20 
conjugated to iodine-
131 
Bexxar Radio-
immunoconjugate 
Relapsed or refractory, 
low-grade, follicular, or 
transformed non-
Hodgkin’s lymphoma 
Daunorubicin DaunoXome Liposomes Kaposi’s sarcoma 
Doxorubicin Myocet Liposomes Combinational therapy 
 16 
of recurrent breast 
cancer, ovarian cancer, 
Kaposi’s sarcoma 
Doxorubicin Doxil/Caelyx PEG-liposomes Refractory Kaposi’s 
sarcoma, recurrent 
breast cancer, ovarian 
cancer 
Vincristine Onco TCS Liposomes Relapsed aggressive 
non-Hodgkin’s 
lymphoma (nHl) 
Paclitaxel Abraxane Albumin-bound 
paclitaxel 
nanoparticles 
Metastatic breast cancer 
 
Pharmacokinetics 
 
Pharmacokinetics is defined as the study of the time course of drug absorption, 
distribution, metabolism, and excretion. Clinical pharmacokinetics is the application of 
pharmacokinetic principles to the safe and effective therapeutic management of drugs in an 
individual patient. Primary goals of clinical pharmacokinetics include enhancing efficacy and 
decreasing toxicity of a patient’s drug therapy. A drug’s effect is often related to its 
concentration at the site of action, so it would be useful to monitor this concentration. 
However, direct measurement of drug concentration at the sites of action i.e. receptor sites is 
generally not practical as we cannot directly sample drug concentration in the tissue, instead 
we can measure the concentration in easily sampled fluids, e.g. blood, plasma, urine, and 
saliva. To predict the relationship between plasma drug concentration and concentration at 
the receptor site, Kinetic homogeneity concept was assumed. It is the assumption that 
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concentrations of a drug in plasma is directly relate to concentrations at the receptor site, 
where a given drug produces its therapeutic effect, as well as in other tissues. As the 
concentration of drug in plasma increases, the concentration of drug in most tissues will 
proportionally increase and vice versa.  
 
A      B 
 
Figure 4. Kinetic homogeneity. (A) Schematic diagram represent kinetic homogeneity 
concept (B) a relationship of plasma to tissue drug concentrations. Figure reproduced from 
[69]. 
 
Pharmacokinetic models 
Administrated drug into the body undergoes several biological processes, such as 
absorption, distribution, metabolism, and elimination, which pose difficulty to predict a 
drug’s behavior in the body and to identify drug concentration in target tissues. In order to 
study the drug’s behavior, various body processes need to be simplified utilizing 
mathematical models. Compartmental models, the basic and widely used models in 
pharmacokinetics, are categorized by the number of compartments needed to describe the 
drug’s behavior in the body. The compartments generally represent a group of organs or 
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tissues in which drug distribution is similar instead of each individual specific organ or 
tissue.  
For example, heart, lungs, liver and kidneys, which are often similar and highly 
blood-perfused, are considered as one compartment, and is usually referred to as the central 
compartment. On the other hand, fat tissue, muscle tissue, and cerebrospinal fluid, which are 
less well perfused, are designated as the other compartment, known as the peripheral 
compartment. Figure demonstrates organs groups for central and peripheral compartments.  
 
 
Figure 5. Typical organ groups for central and peripheral compartments. Figure reproduced 
from [69]. 
 
Compartmental models are deterministic because the observed drug concentrations 
determine the type of compartmental model required to describe the pharmacokinetics of the 
drug. Generally, it is best to use the simplest model that accurately predicts changes in drug 
concentrations over time. If a one-compartment model is sufficient to predict plasma drug 
concentrations (and those concentrations are of most interest to us), then a more complex 
(two-compartment or more) model is not necessary. 
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• One-compartment model 
The one-compartment model is the simplest because there is only one compartment. All body 
tissues and fluids are considered a part of this compartment. Furthermore, it is assumed that 
after a dose of drug is administered, it distributes instantaneously to all body areas [70]. Thus 
the drug concentration–time profile shows a monophasic response (i.e. it is 
monoexponential) and the log drug concentration-time graph shows a liner relation. It is 
important to note that this does not imply that the drug concentration in plasma is equal to the 
drug concentration in the tissues. However, changes in the plasma concentration 
quantitatively reflect changes in the tissues [70].  
 
• Two-compartment model 
However, some drugs do not distribute instantaneously to all parts of the body, even after 
intravenous bolus administration. Commonly, the drug distributes rapidly in the bloodstream 
and in highly perfused organs, and then slowly disperses to other body tissues. This pattern 
of drug distribution is represented by two-compartment model [70]. The drug concentration–
time profile of this model shows a curve but the log drug concentration–time plot shows a 
biphasic response and this can be used to distinguish whether a drug shows a one- or two-
compartment model [70]. 
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Figure 6. Drug distribution in one- and two-compartment models. Figure reproduced from 
[69]. 
The one- and two- compartment model can be represented as in Figure 7. Notably, in 
two-compartment model, drug moves back and forth between these compartments to 
maintain equilibrium. 
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Figure 7. One- and two- compartment models. Figure is modified and reproduced from [69-
71] 
 
• Multi-compartment model 
When the concentration–time profile shows more than two exponentials, it indicates the drug 
distributes into more than two compartments. In this case, multi-compartment model is 
required to explain drug’s behavior in the body and each exponential on the concentration–
time profile describes a compartment. Gentamicin is an example of drug, described by a 
three-compartment model following a single I.V. dose [70].  
 
Pharmacokinetic parameters 
This section briefly review the terminology frequently used in pharmacokinetic study. 
• Volume of distribution 
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Volume of distribution (Vd) is an important indicator of the extent of drug distribution into 
body fluids and tissues. It is defined as the volume of plasma in which the total amount of 
drug in the body would be required to be dissolved in order to reflect the drug concentration 
attained in plasma [70]. The volume of distribution actually has no direct physiological 
meaning and it is usually referred to as the apparent volume of distribution. 
A large volume of distribution indicates that the drug distributes extensively into body tissues 
and fluids. Conversely, a small volume of distribution indicates limited drug distribution in 
tissues, but mainly in the plasma. When Vd is many times the volume of the body, the drug 
concentrations in some tissues should be much greater than those in plasma. The smallest 
volume in which a drug may distribute is the total plasma volume [69]. 
• Distribution and elimination phase 
When drug plasma concentration-time plot after intravenous injection is shown as a semi-
logarithmic plot, two different phases can be distinguished; an initial phase during which the 
plasma concentration steeply decreases i.e. distribution phase, and a second, linear phase 
which is less steep i.e. elimination phase. During the distribution phase, rapid changes in the 
concentration of drug in plasma reflect primarily distribution of drug into the different tissues 
within the body, rather than loss from the body. Once the drug in the plasma and tissues has 
reached equilibrium, during the linear phase in the semi-logarithmic plot, the decline of 
plasma concentration is driven by elimination of the drug from the body [72]. 
• Elimination half-life 
Elimination half-life or terminal half-life is the time required for drug concentration in the 
blood to decrease by 50% after pseudo-equilibrium of distribution has been reached; then, 
terminal half-life is computed when the decrease in drug plasma concentration is due only to 
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drug elimination. It is important to note that elimination half-life is not the time necessary for 
the amount of the administered drug to fall by one half [71]. However, for one-compartment 
model, elimination half-life is simply referred to the time required to reduce the plasma 
concentration to one half its initial administrated value [70]. 
• Clearance 
Drug clearance (CL) is defined as the volume of plasma in the vascular compartment cleared 
of drug per unit time. This drug elimination generally results from liver metabolism and/or 
excretion by the kidneys [72]. Clearance for a drug is constant if the drug is eliminated by 
first-order kinetics. If a drug has a CL of 3L/h, this tells you that 3 litres of the Vd is cleared 
of drug per hour [70]. 
• Area under the curve 
 The area under curve (AUC) is integral of the plasma drug concentration-time curve. It 
reflects the actual body exposure to drug after administration of a dose of the drug and is 
expressed in mg*h/L [72]. This area under the curve is dependent on the rate of elimination 
of the drug from the body and the dose administered. 
• Mean residence time 
Mean residence time (MRT) is the average time the molecule introduced reside within the 
body [73]. MRT value helps interpret the duration of effect for direct-acting molecules. 
 
Biodistribution 
 
Biodistribution is a study of tracking where agents, e.g., compounds, nanoparticles, 
cells, of interest travel in an experimental animal or human subject. The agents usually are 
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modified to contain some tractable moieties, e.g. fluorescent dyes, radioisotopes, or genes 
encoding specific reporter proteins like luciferase and green fluorescent protein. The 
biodistribution study can be performed both non-invasive and invasive manners. Non-
invasive strategy generally refers to imaging of the tracked agents in real time in live animal 
models. The non-invasive method has gained popularity since 1) the tracking can be 
performed over time on the same animal, providing more and conclusive information with 
minimized variation errors, 2) the strategy offers a way to reduce the number of animals 
used, and 3) a wide range of suitable imaging techniques has become available for research 
use. The examples of imaging modalities used for biodistribuion study include 
bioluminescence imaging, fluorescence imaging, Magnetic resonance imaging (MRI), 
positron emission tomography (PET), single-photon emission computed tomography 
(SPECT).  
Regarding invasive biodistribution study, it is usually involved in euthanizating the 
experimental animals at terminated time point, and collecting organs or tissues of interest for 
further analysis of the tracking agent. An example of general procedure, once tested 
compound is injected intravenously into a group of 16-20 mice, at intervals of 1, 2, 4, and 24 
hours, smaller groups (4-5) of the animals are euthanized, and then dissected. The organs of 
interest (usually; blood, liver, spleen, kidney, muscle, fat, adrenals, pancreas, brain, bone, 
stomach, small intestine, and upper and lower large intestine) are harvested and analyzed to 
identify the amount of administrated compounds in each individual tissue. The results give a 
dynamic view of how the compound moves through the animal. The imaging techniques 
mention earlier as well as many other conventional laboratory techniques, e.g. 
immunohistochemical methods, fluorescent/luminescence microplate reader assay and 
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Polymerase chain reaction (PCR), can be implemented to determine the amount of tracking 
compounds presenting in the tissues.  
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CHAPTER 2 
 
INFLUENCE OF SIZE AND SPECIFICITY ON PHARMACOKINETICS, 
BIODISTRIBUTION, AND TUMOR TARGETING OF WIDELY USED 
BIOLOGICS: REQUIREMENT OF SPECIFICITY FOR TUMOR 
INTERNALIZATION 
 
Abstract 
 
Sensitive and specific detection of tumor growth and progression is significant for its 
ability to better diagnose and stage cancer, and to assess tumors’ response to treatment. In 
this endeavor, a variety of biologics have been used, revealing that molecular size and a half-
life in the blood are more dominant parameters for tumor detection than specificity of 
biologics to tumor antigens. However, few studies exist that used widely used biologics in 
parallel to examine the parameters that would influence biodistribution, and tumor 
localization and internalization. Here, we used fluorescently-labeled six different biologics 
(antibodies, antibody fragments, serum albumin, and streptavidin) and measured their 
distribution at whole body, ex-vivo tissue, and cellular levels in mice bearing human cervical 
cancer cells. Although the highest localization into the tumor was obtained with full-length 
antibody specific to tumor antigen, serum albumin and streptavidin were overall superior in 
tumor to blood ratios. To our surprise, Fab format of antibodies, comparable in size to 
albumin and streptavidin, were much inferior in tumor detection to albumin and streptavidin, 
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partly due to faster clearance of Fab from the blood. Despite high level of localization into 
the tumor, neither control antibodies nor albumin and streptavidin were not found inside 
cells. It indicates that specificity to tumor antigen was required for tumor cell internalization 
by biologics. In summary, our study emphasizes that specific tumor detection by molecular 
targeting needs to be validated by comparing its biodistribution and targeting with that of 
control antibodies or other biologics (e.g., albumin). Furthermore, the use of biologics as a 
cytotoxic drug carrier will require specificity to tumor markers in order to achieve not only 
localization but also internalization in tumor cells. 
 
Introduction  
 
Molecular imaging, enabled by contrast agent-conjugated small molecules, 
antibodies, and other recombinant peptides or proteins that are more selective towards tumor 
cells than normal ones, becomes increasingly more important for its ability to better diagnose 
and stage cancer, and to assess tumor response to treatment. Unlike biologic labeling of 
tumors in vitro where affinity and specificity of molecules are dominant factors, in vivo 
tumor detection is much more complex as molecules are first subject to body’s physiology 
before they are distributed in the vicinity of tumors. The factors affecting biologic 
performance in cancer detection in vivo include molecular size and shape, clearance rate 
from blood, specificity, and affinity for target antigens [1-4]. The properties inherent to 
tumor itself also influence sensitivity and specificity of biologics in molecular imaging, such 
as size and tendency for non-specific uptake, vascular and lymphatic supplies, and 
permeability within the tumor [5-8].  
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Previous studies using native antibodies (full-length immunoglobulin (Ig)), 
enzymatically truncated formats (e.g., Fab, (Fab’)2), and various recombinant antibody 
variants (e.g., scFv, scFv-Fc, diabody, triabody) have revealed that selectivity and affinity are 
not the only factors that determine their tumor detection capacity [9-11]. With comparable or 
even lower binding affinity, it has previously been shown that smaller variants of antibodies 
achieved higher tumor-to-blood ratios than that of Ig [11, 12]. Moreover, in another study 
using scFv-Fc with the same size and binding affinity but significantly different clearance 
kinetics, it has disclosed that the fragment versions with shorter serum half-life produced 
clearer tumor images [10]. In these situations the difference in size and clearance rate from 
the body circulation mainly contributed to the outcome, emphasizing the importance of 
pharmacokinetic parameters in molecular imaging. Besides, intriguingly, several studies 
using serum albumin and streptavidin have also demonstrated that much of tumor 
localization by biologics is ascribed to passive diffusion of molecules through leaky 
vasculature within the tumor. This is due to the fact that tumor vasculature is more permeable 
(pore size ~200-600 nm) then normal vessel (pore size less than ~5 nm [2, 13, 14]), except 
vascular sinusoids in the liver, spleen, and bone marrow. Only molecules smaller than the 
vasculature pore sizes are allowed to pass through and extravasate from circulation. Once the 
molecules emigrate and localize in tumors with less developed lymphatic drainage, they can 
be accumulated and retained for a long period of time within the tumor, an effect known as 
enhanced permeability and retention (EPR) effect. The passive tumor targeting then raises an 
interesting question whether and to what extent, Ig or Ig variants with specificity to tumor 
antigens would be superior to similarly sized molecules in imaging and therapy applications. 
 36 
Beyond localization in tumors, defining internalization characteristics of biologics 
becomes a critical issue when the biologics are developed as therapeutic carriers. Drug 
carriers that preferentially deliver drugs to target sites attain selectivity by means of 
molecular targeting, EPR effect, or the combination of both. To date clinically approved drug 
carriers are built with cancer drugs covalently coupled to antibodies or encapsulated within 
nanoparticles (e.g., Doxorubicin containing pegylated liposomes (Doxil) and Paclitaxel 
serum albumin (Abraxane)). Through receptor-mediated endocytosis, antibody-drug 
conjugates are internalized into cells, while non-specific uptake by cells is mainly 
responsible for drug delivery by non-targeted nanoparticle-carriers.  
Despite a plethora of studies demonstrating the influence of size and specificity on 
tumor detection, to our knowledge, there have been few studies that have examined, in 
parallel in the same animal model, widely used biologics for their biodistribution, 
pharmacokinetics, and tumor detection as well as internalization. Here, we have chosen mice 
xenografted with human cervical cancer cells (HeLa) with overexpression of a molecule 
known as intercellular adhesion molecule (ICAM)-1. ICAM-1 is constitutively over-
expressed in many carcinomas including breast, colon, non-small cell lung, and gastric 
tumors compared to respective normal epithelial cells, and in tumor stroma within an 
inflammatory network [7]. In terms of biologics, we used mouse antibody against ICAM-1 
and control antibody, both of them in Ig and fragment antigen binding (Fab) formats. To 
compare how size, specificity, and pharmacokinetics affect tumor detection, we also used 
serum albumin and streptavidin, which are currently being used for drug carrier and imaging 
applications in clinic. Our study shows that biologics such as serum albumin and streptavidin 
with optimum size and clearance rate can outperform similarly sized molecules with 
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specificity to tumor antigens. However, for internalization of biologics into tumors, we found 
that specificity to tumor antigen is essential. 
 
Materials and methods 
 
Mammalian cell culture 
HeLa, and HEK 293 cells (ATCC) were cultured in Advanced Dulbecco’s modified 
Eagle’s medium containing 10% (v/v) fetal bovine serum, 2 mM L-alanyl-L-glutamine 
dipeptide, and 100 U/ml Penicillin-Streptomycin (all from Invitrogen) at 37°C in a 5% CO2 
humidified incubator.  
 
Purification of monoclonal antibody R6.5 IgG and enzymatic fragments 
A mouse R6.5 or R6-5-D60 IgG2a was produced by a mouse-mouse hybridoma cell 
line; R6.5.D6.E9.B2, also called R6-5-D60 (ATCC® HB-9580™) [15]. The hybridoma cells 
were maintained under culture conditions listed on the ATCC website 
(http://www.atcc.org/products/all/HB-9580.aspx#culturemethod). In summary, the cells were 
propagated in RPMI 1640 medium supplemented with 10% (v/v) fetal bovine serum, 2 mM 
L-alanyl-L-glutamine dipeptide, 100 U/ml Penicillin-Streptomycin, and 5 µg/ml Plasmocin™ 
(InvivoGen) at 37°C in a 5% CO2 for a few passages before antibody production. Maintain 
cultures at a cell concentration between 3×104 and 5×105 cells/ml during propagation. The 
cells were then switched to CD Hybridoma media with 2 mM L-alanyl-L-glutamine 
dipeptide, 100 U/ml Penicillin-Streptomycin, and 5 µg/ml Plasmocin™ during antibody 
production process. R6.5 IgG was affinity purified from cell culture supernatants using Affi-
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Gel® Protein A MAPS™ II Kit (Bio-Rad). Eluted fractions were immediately neutralized, 
concentrated using 10 kDa cut-off Amicon Ultra-15 Centrifugal Filter Units (EMD 
Millipore) and desalted into phosphate-buffered saline (PBS) upon PD-10 Desalting Columns 
(GE Healthcare). Fab fragments were generated by the digestion of the purified IgG with 
papain, as previously described [16]. Briefly, one volume of 2 mg/ml purified R6.5 IgG in 
PBS, pH 6.2 was incubated at 37°C for 15 h with one volume of 0.02 mg/ml papain (Sigma-
Aldrich) in freshly prepared digestion buffer, PBS containing 0.02M 
ethylenediaminetetraacetic acid disodium salt and 0.02M cysteine (both from Sigma-
Aldrich), pH 6.2. The Fab fragments were separated from the other digestion products, Fc 
and undigested IgG, by Affi-Gel® Protein A MAPS™ II Kit followed by buffer exchange 
into PBS using PD-10. The protein concentration of purified antibody and fragment was 
determined by NanoDrop (Thermo Scientific).  Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) was further used to qualitatively analyze purified antibody as 
well as digestion products.  
 
In vitro binding and internalization assays 
Biologics used for this study include a murine anti-human ICAM-1, R6.5 IgG, mouse 
IgG from mouse serum (Sigma-Aldrich), Fab fragments of R6.5 and control IgG, streptavidin 
(Invitrogen), and bovine serum albumin (BSA) (Fisher Scientific).  Prior to binding and 
internalization study, Alexa Fluor® 488 sulfodichlorophenol ester (Alexa488) and Alexa 
Fluor® 750 succinimidyl esters (Alexa750) were covalently conjugated to the biologics. 
Degree of labeling (D.O.L.) of each dye was determined using Nanodrop following the 
manufacturing protocol. To test biologic binding in vitro, HeLa and HEK 293 cells were 
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trypsinized and washed with ice-chilled complete cell culture medium. 10 µg/ml Alexa 
Flour® labeled biologics were incubated with cells (200,000 cells per labeling sample) in 50 
µl completed cell culture medium on ice for 1 h. Cells were washed twice in 300 µl of 
completed cell culture medium. After final washing, cells were resuspended in 300 ml PBS 
and subjected to flow cytometer (BD-Biosciences LSRII Flow Cytometer). For quantitative 
uptake evaluation, the biologic labeled cells were chased for 0, 1 or 3 h in cell culture 
medium at 37°C. At the end of chasing time, cells were rapidly chilled and half the samples 
were incubated on ice for 2 h with (surface quenched samples) or without (unquenched 
samples) 25 ug/ml rabbit anti-Alexa488 (Molecular Probes, Invitrogen A11094) in 70 µl 
complete cell culture medium. The cells were then washed twice before FACS analysis. The 
amount internalized was calculated from collected mean fluorescence intensity data after 
correcting for incomplete surface quenching, as previous described [17, 18] 
 
Subcutaneous tumor model and biologic treatments 
HeLa cells (3×106) suspended in 1:1 PBS: Matrigel (BD) mixture in a total volume 
of 150 µl were injected subcutaneously on the back around lower flank area of 4-wk-old 
female, severe combined immunodeficiency (SCID) hairless outbred (SHO) mice, approx. 
weight 20 g (strain code: 474, Charles River Laboratories). Tumor growths were measured 
using a vernier caliper and the tumor volumes were calculated by formula: 0.5 × length × 
(width)2. When tumors reached approximately 150 mm3, the animals were randomized into 
eight different groups (n = 3) and were treated with the same mass (100 µg) of different 
fluorescently-labeled biologics in sterile PBS buffer (200 µL) via retro-orbital injections 
using 29G insulin syringes.  R6.5 and control IgG groups were each conducted with 2 
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terminal time points; 24 and 168 h. All animal experiments were performed in compliance 
with the guidelines of the Institutional Laboratory Animal Use and Care Committee of 
Cornell University.  
 
Pharmacokinetic studies 
After biologic administration, the blood (30 µL) was collected at different time points 
through the submandibular vein using 22G needles. The plasma (15 µL) was separated from 
whole blood by centrifugation (5000×g, 10 min). The collected plasma was kept at -20°C 
until analysis. The fluorescent signal from the plasma (10 ul in black 384 well microplates 
(Corning)) was measured by a microplate reader (Bio-Tek). The amount of biologics was 
quantified according to a standard curve, which was achieved by adding various amounts of 
the test materials to the plasma of an untreated mouse. The pharmacokinetic parameters were 
determined by fitting the percentage of injected dose per milliliter of blood (% ID/mL) versus 
time (h) curve into a two-compartmental pharmacokinetic model using PK Solver Microsoft 
Excel plug-in freeware as described previously [19]. 
 
In vivo imaging and biodistribution studies 
In vivo imaging was performed in real-time by optical imaging using a Xenogen 
IVIS-200 (Perkin Elmer). Mice were anesthetized with 5% isoflurane (VetOne) before they 
were placed in the Xenogen and maintained at 2% isoflurane during whole body imaging. 
The whole body fluorescence images were acquired using the ICG channel at different time 
points.  At the terminated time point, the mice were euthanized, the tumor and major tissue 
and organs were dissected, and ex vivo fluorescence images were obtained. Images and 
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measurements of fluorescent signals were acquired and analyzed with Living Image 
software. The fluorescent signal measurement data of biologic materials prior to injection 
were used to quantify the amount of biological materials in each organ. The biodistribution 
of the biologics in various organs was then calculated and normalized in unit of percentage of 
injected dose per gram of tissue (% ID/g). 
 
In vivo internalization detection 
Collected tumors at terminated time points (24 or 168 h post biologic administration) 
were dissociated using collagenase A (Roche) as described previously [20]. In brief, tumors 
were minced and digested in 1 mg/ml collagenase A in complete DMEM medium for 2 h at 
37 C. Singlet lung cells were prepared by passage through 70 µm nylon mesh cell strainer 
(BD Falcon) and incubation with red blood cell lysis buffer (eBiosciences, San Diego, CA, 
USA) for 20 min at room temperature. Cells were then washed and divided into 2 groups, 
100,000 cells each, with and without surface fluorescence quenching by the rabbit anti-
Alexa488. The samples were then subjected to FACS analysis. Internalized fluorescence was 
calculated from quenched and non-quenched sample data as described earlier in 2.3 In vitro 
binding and internalization assays. 
 
Statistical analysis 
Data were expressed, unless otherwise stated, as mean ± standard error of the mean 
(SEM), of no smaller than triplicates. Statistical analysis of data was performed using 
GraphPad Prism 5 (Graphpad Software). Differences with p values < 0.05 were considered 
significant. Student's t-Test was used for testing the difference between two means (Fig. 6B). 
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Two-way ANOVA was used to compare the mean responses of different biologic treatments 
to different time points or to different tissues, followed by Bonferroni post-hoc test to 
determine statistical significance (Fig. 2A, Fig. 3C,D, & Fig. 4B).  
 
Results 
 
Preparation of biologics, in vitro assays to confirm ICAM-1 dependent binding  
Natural IgG and enzymatically truncated or recombinant variants of IgG have been 
the dominant sources of biologics for molecular imaging applications. Besides antibodies, 
two other widely used biologics include bovine serum albumin and streptavidin for their 
superior in vivo safety and pharmacokinetics. In this study, ICAM-1 specific monoclonal 
antibody (mAb), R6.5 (mouse IgG2) in native and Fab formats were used to selectively bind 
ICAM-1 positive HeLa cells. As a control for R6.5, polyclonal IgG purified from mouse 
serum was used. In total, we examined six different biologics, differing in size (50-150 kDa) 
and specificity to ICAM-1, in mice bearing subcutaneous HeLa xenograft (Fig. 1A).  
mAb R6.5 was produced from hybridoma (~20 mg/L of culture supernatant), and 
purified to >95% purity (Fig. 1B). Fab fragments of both R6.5 and control IgG were 
produced by treating antibodies with papain, followed by removal of antibody Fc fragment 
with protein A column (Fig. 1C). Under a reducing condition of SDS-PAGE, Fab migrated as 
two bands of heavy and light chain fragments. To confirm size and purity, all six biologics 
were purified and analyzed by non-reducing SDS-PAGE (Fig. 1D). Mouse IgG migrated into 
at least two distinct bands, indicative of polyclonality consisting mainly of IgG1 and IgG2 
isotypes. Streptavidin (~52 kDa) and BSA (~66 kDa) migrated close to their theoretical  
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Figure 1. Preparation of biologics and in vitro assays to confirm ICAM-1 dependent binding. 
(A) Schematic illustration and sizes of studied biologics. Coomassie blue stained 12% SDS-
PAGE analysis of (B) protein A purified R6.5 IgG under non-reducing (NR) and reducing 
(R) conditions, (C) R6.5 fragments from enzymatic fragmentation under reducing condition, 
and (D) the studied biologics under non-reducing condition. (E) Flow cytometry histogram 
illustrates specific binding of R6.5 to ICAM-1. Constitutive ICAM-1 expressing HeLe cells 
and negative ICAM-1 expressing HEK 293 cells were incubated with Alexa488-labeled R6.5 
and control IgG, washed, and analyzed by FACS. Autofluorescence of cells without labeling 
is shown in solid filled histogram. 
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molecular weights; both Fab fragments of R6.5 and control antibody exhibited faster 
mobility, migrating with nominal molecular weight of 40 kDa. To confirm specificity to 
ICAM-1 in vitro and in vivo assays, biologics were labeled with two different fluorescent 
dyes (Alexa488 and Alexa750). Labeling condition was adjusted to add on average, 1.2-1.5 
dyes of each kind to one biologic molecule. The specificity of R6.5 against ICAM-1 was 
confirmed by selective binding to ICAM-1 positive HeLa but a lack of binding to ICAM-1 
negative HEK 293 cells. Control IgG, BSA, and streptavidin exhibited no discernible binding 
above background levels to either HeLa or 293 cells (Fig. 1E and data not shown). 
 
Measurement of biologics’ pharmacokinetics 
Prior to imaging biologics for biodistribution in mice, we first examined 
pharmacokinetics of each molecule by measuring its concentration in the blood over 1 or 7 
days postinjection, which was plotted as the percentage of injected dose per milliliter of 
blood (%ID/mL) versus time (days) (Fig. 2A). These measurements were then used to fit the 
two compartmental PK model, which is characterized by an initial rapid clearance from the 
central compartment (blood and well perfused organs) to the peripheral compartment (poorly 
perfused tissues) (described by rate constants, K12 and K21) and a slower rate of clearance due 
to an elimination from the central compartment (rate constant, K10) (Fig. 2B). From this 
model, standard pharmacokinetic parameters were obtained that include distribution and 
elimination half-lives (t1/2(α) and t1/2(β)), area under the curve (AUC), mean residence time 
(MRT), clearance from the central compartment (CL), and volume distribution (Vd). The 
elimination half-lives of both R6.5 (IgG2a) and control IgG (polyclonal mixture) in young 
SCID mice were ~2 days, considerably faster than the half-lives measured in adult normal  
 45 
 
 
 
Figure. 2. Pharmacokinetic study. (A) Plots of the pharmacokinetic profile of the studies 
biologics. All the fluorescence-labeled biologics (100 mg) in sterile PBS buffer were 
intravenously administered into SCID mice (n = 3 for each group of animals). Blood samples 
were collected at different time points and analyzed for biologic concentrations. The data 
were plotted as a percentage of injected dose in blood (% ID/mL) versus time. Error bars are 
SEMs. For R6.5 and control IgG (*p < 0.05, ***p < 0.001, n = 3 (except at 1, 4, 12 and 24h 
post injection time points, n = 6)). (B) Scheme of two compartment pharmacokinetic model. 
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mice (6-8 days). Despite small difference in molecular mass, Fab fragments of R6.5 and 
control IgG were cleared much faster from the blood (~1 h) than BSA and streptavidin (4-5 
h) (Fig. 2A & Table 1), likely due to a rapid clearance of Fab through renal filtration (~60 
kDa of cut-off molecular mass). 
 
Whole body imaging of biologics in mice bearing human tumors 
Six different biologics labeled with near-infrared (NIR) fluorescent dyes were then 
compared for their biodistribution in mice xenografted with HeLa tumors (Fig. 3). Overall, 
highest accumulation into tumors was associated with ICAM-1 specific antibody, R6.5, 
which persisted up to 7 days after injection. Consistent with faster clearance of Fab from 
circulation, bright signals were detected in the kidneys of the mice injected with Fab. Despite 
being specific to HeLa, R6.5 Fab was marginally better than Fab of control antibody in 
delineating tumors. In comparison, BSA and streptavidin, which would localize to the tumors 
through EPR effect, provided higher signals in the tumor than Fab fragments. When the 
signal intensity within the tumor region was normalized to the tumor weight (%ID/g), in 
agreement with a visual grading of biologics in tumor detection, the time between injection 
and peak intensity was shortest with R6.5 Fab fragments (~1 h), followed by 
BSA/streptavidin (~4 h), and R6.5 IgG (~24 h). The elapsed time to peak intensities in the 
tumor were overall in correlation with the elimination half-lives (Fig. 3C&D and Table 1).  
 
Biodistribution quantification of biologics at tumor and organ levels 
Whole body imaging of NIR dyes is biased to detection of biologics distributed closer to the 
skin, requiring isolation and imaging of the major organs and tumors for quantitative  
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Figure 3. Real-time whole body imaging and tumor accumulation. (A, B) The merged 
fluorescence and bright field images of HeLa-implanted SCID mice (n = 3 for each group of 
animals) at different time points after intravenous administration of the fluorescence labeled 
biologics. (C,D) A comparison of tumor accumulation profile of the injected biologics. 
Images and measurements of tumor localized fluorescence signals were acquired and 
analyzed with Living Image software. Error bars are SEMs (*p < 0.05, **p < 0.01, ***p < 
0.001, n = 3 (except R6.5 and control IgG at 1, 4, 12 and 24h post injection, n = 6)). 
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mapping of biologics in the body. After mice were euthanized, major organs (lungs, heart, 
spleen, kidneys, brain, and liver) and tumors were isolated and subjected to ex vivo NIR 
imaging (Fig. 4A). In agreement with whole body level imaging of tumor detection at 24 h 
postinjection, the localization of biologic into the tumor was highest with R6.5, followed by 
control IgG, streptavidin, and BSA, and lowest with Fab. At 7-days after injection, signals 
from R6.5 were still persistent, far higher than those in the lungs and liver (Fig. 4). The 
uptake of biologics by the immune cells in the mononuclear phagocytic system (MPS) would 
produce signals in the liver, lungs, and spleen. The signal intensity (%ID/g) from the liver at 
24 h was significantly higher than that from the tumor in control IgG, Fab fragments, and 
BSA groups.  Contrarily, these live-tumor signals are comparable in the cases of R6.5 IgG 
and streptavidin.  
By 7 days postinjection, the signal intensity of R6.5 IgG in the tumor was the only 
signal reliable detectable among other tissues. Although being foreign antigens in the body of 
mouse, BSA and streptavidin localization to MPS organs at 24 h were not significantly 
different from those of mouse IgGs (Fig. 4).  
 
Validation of in vitro assays to confirm ICAM-1 specific internalization 
Biologics that not only localize but also internalize into tumors will be advantageous 
as a molecular probe as their association with the site of tumors would be longer than the 
molecules residing outside of cells. For the use of biologics as drug carriers, internalization 
into cells via specific molecular interaction may be a key to achieve targeted cell death. The 
magnitudes and kinetics of internalization into cells were investigated using anti-AF488 
antibody, which bind and quench AF488 that is covalently coupled to biologics. Therefore, 
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Figure 4. Biodistribution of biologics at tumor and major organs. The merged fluorescence 
and bright field images (A) and a bar chart shows the percentage of injected dose (% ID/g of 
tissue) ± SEM (B) of harvested HeLa tumors and different organs at 24h and 7d post biologic 
administration (n = 3 for each treatment group).  
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the higher degrees of reduction in fluorescence intensity after quenching with anti-AF488 
antibody, the more biologics remain bound on cell surface without internalization. For this 
assay, HeLa was first labeled with R6.5 and Fab fragment of R6.5 at 4°C to prevent antibody 
internalization, and a subset of R6.5 labeled cells was subsequently incubated with anti-
AF488 antibody. As shown in Fig. 5A, the level of fluorescence labeling was much higher 
with R6.5 IgG than Fab, indicating that monomeric interaction between R6.5 Fab and ICAM-
1 was not high affinity and could be greatly dissociated during washing steps. After anti-
AF488 antibody labeling, there was substantial fluorescence reduction in both cases, 
amounting to approximately 92±4% and 88±3% decreases for IgG and Fab, respectively. To 
investigate the degree of internalization of R6.5 IgG and Fab, surface labeled cells were then 
incubated at 37°C for 1 and 3 hours to induce antibody internalization. The reduction of 
fluorescence after addition of AF488 antibody was then used to compute the amount of R6.5 
IgG and Fab internalization. After 3 h incubation at 37°C, the level of internalization was 
comparable for both R6.5 IgG and R6.5 Fab at ~20%  (Fig. 5A&B).  
 
Specific interaction is required for cell binding and internalization 
We then examined the level of tumor binding and internalization of all the studied 
biologics after i.v. administration. For this assay, singlet cells were isolated from the 
harvested tumors. The cells were then subjected to flow cytometry to measure the amount of 
biologics associated with HeLa cells, from the combination of both cell surface binding and 
internalization (Fig. 6A&B). To our surprise, there was little signal associated with non-
ICAM-1 binding biologics, independent of the level of tumor localization. This suggests the 
biologics passively accumulated into the tumor through EPR effect remained outside of cells  
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Figure 5. In vitro assays to confirm ICAM-1 specific internalization. (A) HeLa cells were 
bound with 1 ug/ml Alexa488-labeled R6.5 IgG or Fab variants on ice, washed and chased 
for 0, 1, or 3 h at 37°C ( Biologics). Half of the samples were surface quenched with anti-
Alexa488 ( Biologics+anti488) prior to FACS analysis. (B) Internalization and surface 
fractions of ICAM-1 bound R6.5 IgG and Fab are shown in bar graph as MFI ± SEM (n=3). 
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Figure 6. Specific interaction is required for cell binding and internalization (A) Binding and 
internalization study of the biologics into HeLa cells isolated from xenograft tumors. 
Collagenase-digested tumors, collected at 24h and 7d post biologic injections ( Biologics) 
were halved and surface quenched with anti-Alexa488 ( Biologics+anti488) prior to FACS 
analysis. Digested tumors from non-treated mice were also collected and measured for 
autofluorescence ( No label). (B) MFI measured by FACS in Fig. 6A are quantitatively 
shown in bar graph. (C) Internalization and surface fractions of ICAM-1 bound R6.5 IgG and 
Fab were shown in bar graph. All error bars in this figure denote SEM (**p < 0.01, ***p < 
0.001, n = 3). 
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and were washed out in the course of cell isolation. On the other hand, both R6.5 IgG and 
Fab were found to label the isolated HeLa cells remarkably. From the amount of fluorescence 
quenching by anti-AF488 antibody, the percentage of R6.5 IgG internalized into cells was 
determined to be as much as 50-65%. The degree of internalization was even higher with 
R6.5 Fab, reaching ~80%, ascribed to lower affinity of R6.5 Fab, which would enable only 
internalized Fab to be associated with HeLa cells. 
 
Discussion 
 
Biologics labeled with contrast agents for optical imaging, MRI, and PET have been 
actively developed for early and sensitive detection of cancers utilizing specific-targeting 
biomarkers. However, the presence of leaky vasculature and hypotension within the tumor, 
and inherent difference in vascularity and leakiness in different types of tumors present 
challenges to determining relative contribution of specific molecular interaction versus EPR 
effect on tumor localization. In order to study the influence of specificity and 
pharmacokinetics of biologics on tumor localization, we used IgGs and Fab fragments, and 
other widely used biologics, i.e., serum albumin and streptavidin, to examine in parallel 
tumor localization and internalization in mice xenografted with human cancer cells. Our 
studies recapitulated prior studies that biologics such as albumin and streptavidin, due to their 
ideal size and plasma half-life in the blood, are useful reagents in tumor detection by EPR 
effect. As a matter of fact, the amount of albumin and streptavidin localized to the tumor was 
better than ICAM-1 specific Fab fragments with a shorter half-life in blood, reaffirming the 
caution that targeting by IgG variants, such as scFv and Fab, was to a great extent from EPR 
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effect. However, of biologics comparable in size and pharmacokinetics, specificity to target 
antigen was associated with higher accumulation into tumors and more importantly binding 
and internalization into tumor cells.  
The biologics used for detecting tumor locations and even tumor phenotype, e.g., 
expression of specific biomarkers, need to be determined for the best time window for 
imaging after injection to maximize detection sensitivity and signal-to-noise ratios. Our study 
suggests that the time-to-peak intensity of Fab fragments and non-antibody biologics in 
tumor detection was almost equal to their elimination half-lives in the blood, i.e., ~1 h for 
Fab fragments and 4 h for serum albumin and streptavidin. In the case of IgGs, the highest or 
near highest intensity was observed ~24 h, falls between the time to reach 50% reduction in 
concentration (~12 h) and the elimination half-lives (~50 h). However, the signals of most 
biologics used in this study were significantly lower in the tumor than those in the liver at 24 
h after injection. R6.5 IgG showed almost comparable signals between the tumor and the 
liver at 24 h, and by 7 days postinjection, tumor was the only tissue that retained significant 
level of R6.5. Although, no intermediate measurements were performed between 24 h and 7 
days, by interpolating the changes of R6.5 in the ratios of tumor to other organs, it is likely 
that as early as 2 days postinjection, the signal in the tumor would be far above the signals in 
other tissues.  
One of the most important findings in our study is the demonstration that specific 
molecular interaction was necessary for biologics to bind and enter cells. Biologics taken by 
cells would then largely avoid gradual clearance by the body, and increase signal-to-noise 
ratios in tumor detection. Of particular importance is the ability to go inside target cells if 
biologics are to be used to as a carrier of therapeutics, e.g., antibody-drug conjugates. This is 
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to a considerable degree in contrast to prior observations with nanoparticles where 
nanoparticles as drug carriers can be taken up by cells without specific molecular 
interactions. Particle-based drug carriers would be superior in the aspect of delivering a large 
content of drugs per particle, superior specificity to target cells attained by antibodies may 
compensate for the lower ratio of drug to biologic ratios. 
In summary, our study underscores the influence of size and pharmacokinetic 
parameters of biologics on tumor localization, and emphasizes the need for careful 
examination of biologic biodistribution in evaluating tumor phenotypes. 
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CHAPTER 3 
 
INFLAMED LEUKOCYTE-MIMETIC NANOPARTICLES FOR 
MOLECULAR IMAGING OF INFLAMMATION 
 
Abstract 
 
Dysregulated host inflammatory response causes many diseases, including cardiovascular 
and neurodegenerative diseases, cancer, and sepsis. Sensitive detection of the site of 
inflammation will, therefore, produce a wide-ranging impact on disease diagnosis and 
treatment. We hypothesized that nanoprobes designed to mimic the molecular interactions 
occurring between inflamed leukocytes and endothelium may possess selectivity toward 
diverse host inflammatory responses. To incorporate inflammation- sensitive molecular 
interactions, super paramagnetic iron oxide nanoparticles were conjugated with integrin 
lymphocyte function-associated antigen (LFA)-1 I domain, engineered to mimic activated 
leukocytes in physiology. Whole body optical and magnetic resonance imaging in vivo 
revealed that leukocyte-mimetic nanoparticles localized preferentially to the vasculature 
within and in the invasive front of the tumor, as well as to the site of acute inflammation. 
This study explored in vivo detection of tumor-associated vasculature with systemically 
injected inflammation-specific nanoparticles, presenting a possibility of tumor detection by1 
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inflamed tumor microenvironment. 
 
Introduction 
 
Dysregulated inflammatory responses of the host are implicated in the pathogenesis 
of many human diseases [1]. Acute inflammation from infection can cause sepsis [2], while 
chronic inflammation, and continual coexistence between acute and chronic inflammation are 
associated with various neurodegenerative [3] and cardiovascular diseases [4], metabolic 
disorders [5], and cancer [6,7]. Accordingly, sensitive and early detection of inflammation 
and site-specific delivery of anti-inflammatory agents will have a wide-ranging impact on the 
treatment of various inflammation-related diseases. Upon induction of inflammation, a set of 
adhesion molecules is upregulated in endothelium, with which immune cells interact using 
counter adhesion molecules such as integrins to adhere to endothelium and to initiate 
diapedesis. Many existing studies have investigated targeted nanoparticles for the detection 
and treatment of inflammation employing antibodies or peptides specific to adhesion 
molecules such as intercellular adhesion molecule (ICAM)-1 [8-10], vascular cell adhesion 
molecule (VCAM)-1 [11-13], selectins [14], and collagen [15], all of which display distinct 
spatiotemporal responses to inflammation. Among these molecules, ICAM-1 has caught a 
particular interest because of its highly inducible and localized expression upon 
inflammatory signals, serving as a marker for inflammation despite its constitutive low level 
expression [16,17]. 
In this study, we developed nanomicelle encapsulating super paramagnetic iron oxide 
(SPIO) nanoparticles, designed for facile and robust conjugation with targeting moieties and 
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in vivo detection by optical imaging and magnetic resonance imaging (MRI). In order to 
design nanoparticles to mimic the behavior of inflamed leukocytes in their ability to locate to 
the inflamed site, SPIO nanoparticle was coated with an optimum number of high affinity 
inserted (I) domain of integrin called lymphocyte function-associated antigen (LFA)-1 [18], a 
physiological receptor for ICAM-1. Leukocyte-mimetic nanoparticles were examined for 
detection of ICAM-1 overexpression in tumor cells, tumor vascular microenvironment, and 
acute inflammation in vivo. With our recently developed MRI technique for quantitative 
mapping of contrast agent [19,20], we explored the possibility of quantitative spatiotemporal 
mapping of iron oxide distribution in vivo using a mouse model of acute inflammation. 
 
Materials and methods 
 
Preparation and characterization of protein coated SPIO nanomicelles 
Oleic acid-capped super paramagnetic iron oxide (SPIO) nanocrystals (Ocean 
Nanotech, LLC) in 5 mg were suspended in 1 ml chloroform with 12 mg 
1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-
2000](DPPE-PEG) and 3 mg 1,2-dioleoyl-sn-glycero-3-[(N-(5-amino-1-carboxypentyl)-
iminodiacetic acid)succinyl] nickel salt (DOGS-NTA) (Avanti Polar Lipids, Inc.). For 
radiolabeled nanoparticles, 60 µCi of L-α-Dipalmitoyl-Phosphatidylcholine, [Choline-
Methyl-3H] (Perkin Elmer) was also added at this step. After 10 min sonication and 
overnight desiccation, 1 ml of water was added to the residue to form a micelle layer on 
SPIO. After another 10 min sonication and filtration through 0.22 µm filters (Millipore), 
optically clear suspension containing SPIO micelles were obtained. Empty micelles without 
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SPIO in the core were removed by ultracentrifugation. SPIO nanoparticles were purified and 
resuspended in pH 7.4 phosphate-buffered saline (PBS) by size exclusion S200 column (GE 
Healthcare). The wild-type (wt), D137A, and F265S/F292G mutants of LFA-1 I domains 
fused to His tag (6 histidine residues) at the N-terminal were produced as previously 
described [17]. Conjugation of SPIO with His tagged I domains was obtained by incubation 
at 4 °C overnight. Free proteins were removed by size exclusion. All fluorescently labeled 
SPIO nanoparticles were prepared by covalently conjugating Alexa Fluor (AF) succinimidyl 
esters (Invitrogen) to the I domains. Conjugation of fluorescence dyes to the proteins rather 
than to phospholipid was chosen due to significant fluorescence quenching between iron 
oxide and AF-phospholipids. The coating density of proteins on SPIO was determined from 
the ratio of SPIO amount (OD600nm 1 = 0.42 mg/ml) and the concentration of the proteins 
bound to SPIO (by Lowry’s method). Specific activities of radiolabeled SPIO were measured 
by scintillation counter (Beckman Coulter LS6500). Dynamic light scattering (DLS, Malvern 
Instruments) was used to measure the average hydrodynamic size of SPIO after assembly and 
protein conjugation. Transmission electron microscopy (TEM; FEI Tecnai) images of SPIO 
were also taken before and after protein conjugation. 1% uranyl acetate was used for protein 
staining. 
 
Cell culture 
All mammalian cells used in this study were cultured in Advanced Dulbecco’s 
modified Eagle’s medium containing 10% (v/v) fetal bovine serum and 2 mM L-glutamine 
(Invitrogen) at 37 °C in a 5% CO2 humidified incubator. For induction of inflammation, 
bEnd.3 (ATCC) cells were treated with 1 µg/ml of LPS (Escherichia coli. 026:B6, Sigma) for 
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12 h. HeLa and 293T cells stably expressing GFP were established using pSMPUW-miR-
GFP/Puro Lentiviral Expression Vector system (Cell Biolabs). 
 
Immunofluorescence flow cytometry 
Cells were trypsinized and washed once with the ice-chilled labeling buffer (pH 7.4 
PBS, 1% (w/v) BSA, 1 mM MgCl2). 100,000 cells were incubated in 100 µl of the labeling 
buffer for 30 min on ice with 10 µg/ml of Alexa Fluor labeled proteins or SPIO conjugated 
with the same amount of proteins. For competition assay, 50 µg/ml of unlabeled proteins 
were included in the labeling buffer during incubation. Cells were washed twice and 
resuspended in 300 µl of the labeling buffer and subjected to flow cytometer (Beckman 
Coulter EPICS XL-MC). 
 
Microscopy visualization of cell labeling in vitro 
For immunofluorescence microscopy detection of protein labeling, cells were plated, 
washed in pH 7.4 PBS, and fixed with 4% paraformaldehyde for 15 min. After washing three 
times, cells were incubated with 10 µg/ml of Alexa Fluor labeled proteins in PBS/Triton (pH 
7.4 PBS, 0.3% (v/v) Triton X-100, 1 mM MgCl2) at room temperature for 1 h. Cells were 
rinsed once with pH 7.4 PBS and twice with high salt PBS (pH 7.4 PBS, 0.4 M NaCl, 1 mM 
MgCl2). 300 nM DAPI (4,6-diamidino-2-phenylindole, Invitrogen) in PBS was then added 
and incubated for 10 min for nucleus staining. Stained cells were washed and imaged with a 
confocal microscope (Zeiss LSM 710). For detection of SPIO labeling, HeLa cells were 
plated and incubated with 50 µg/ml of SPIO coated with Alexa fluor 488 conjugated proteins 
in culture media for 2 h at 37 °C. Cells were washed in pH 7.4 PBS, incubated for 1 h in 
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serum-free medium for chasing, and imaged using confocal microscopy (Leica TCS SP2). 
After fluorescence imaging, cells were then prepared for Perl’s Prussian blue staining for iron 
detection. Labeled cells were fixed with 4% paraformaldehyde, followed by incubation in a 
freshly prepared solution of 2% potassium ferrocyanide in 2% HCl for 20 min and 
counterstaining with 1% neutral red. 
 
Magnetic cell labeling and quantification 
Trypsinized cells were incubated for 4 h at 37 °C in the labeling buffer (PBS, 1 mM 
MgCl2) under constant rotating with different concentrations of radiolabeled SPIO, washed 
and then fixed in 4% paraformaldehyde. Cells were divided into two conditions, half of 
which were used for radioactivity measurement using scintillation counter (Beckman Coulter 
LS6500), while the remaining half for MRI scanning and QSM measurement after imbedding 
in 100 µl 2% agarose block. MR imaging of the magnetically labeled cells were performed 
on a 3T MRI scanner (Signa, GE, Milwaukee, WI). A 3D multi-echo gradient sequence was 
used to sample multiple TEs in one TR. Imaging parameters were as follows: TEs 3.696 ms, 
4.196 ms, 5.696 ms, 11.696 ms, 35.696 ms; TR 40 ms; flip angle 30°; matrix size 256 × 64 × 
64; voxel size 500 µm3 isotropic. A 3D Fourier transform was applied to the raw k-space data 
to reconstruct T2* weighted images. QSM was obtained through Multiple Orientation 
Sampling (COSMOS) technique, as previously described [19]. 
 
Subcutaneous tumor model 
3×106 human cervical cancer HeLa cells and human embryonic kidney 293T cells 
stably expressing GFP mixed in Matrigel (BD) were injected bilaterally into the front lower 
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flank areas of 8-wk-old female nude mice. Mice were used for experiments 16-20 days after 
injection when tumor size reached about 300 mm3. All animal experiments were conducted 
in compliance with the regulations defined by the Institutional Laboratory Animal Use and 
Care Committee of Cornell University. 
 
Acute LPS-inflammation model 
For subcutaneous LPS, 1 mg/ml LPS in 100 µl PBS and 100 ml PBS were injected 
bilaterally into the lower flank areas of 8-wk-old female BALB/c mice. For systemic LPS, 1 
mg/ml LPS in 100 µl PBS were injected into 8-wk-old female BALB/c mice. Prior to 
imaging hair was removed to reduce background fluorescence. 
 
Near-IR optical imaging of mice 
Animals were anesthetized with isoflurane mixed with oxygen at 5% and maintained 
at 2% isoflurane during whole body imaging (Olympus, OV100). Mice were administered 
with SPIO coated with AF750-conjugated proteins in 150 µl PBS via retro-orbital injection. 
500 and 100 µg of SPIO were used for tumor imaging and acute inflammation models, 
respectively. Near-IR images were taken at different time points post-injection of SPIO. 
Tumor growth was detected by imaging green fluorescence. Image analysis was performed 
with Matlab R2007a (MathWorks). 
 
MR imaging of mice with acute inflammation 
For subcutaneous LPS model, prior to nanoparticle injection mice were exposed to 
LPS/PBS for 12 h. At 4 h after injection of SPIO in 150 µl PBS, mice were euthanized by 
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intraperitoneal injection of 2.5% tribromoethanol (20 µl/g), transcardially perfused with PBS, 
and fixed in paraformaldehyde. Prepared mice were scanned on a 7T scanner (Bruker 
BioSpin, Biospec 70/30 USR) with 3D FLASH sequence. Imaging parameters were as 
follows: TEs (echo time) 5 ms, 6 ms, 30 ms, 35 ms; TR (repetition time) 35 ms; excitation 
pulse angle 15°; matrix size 150 × 150 × 100; voxel size 200 mm3 isotropic; NEX 1. A 3D 
Fourier transform was applied to the raw k-space data to reconstruct the images [19]. For 
systemic LPS model, prior to nanoparticle injection mice were exposed to LPS for 12 h. At 1, 
8, and 25 h post-injection of SPIO coated with proteins in 150 µl PBS, mice were euthanized 
likewise. Prepared mice were scanned on a 3T scanner (GE Signa Excite) with 3D multi-
echo EFGRE sequence [19]. Imaging parameters were as follows: TEs 3.696 ms, 4.196 ms, 
5.696 ms, 11.696 ms, 35.696 ms; TR 40 ms; flip angle 30°; matrix size 256 × 64 × 64; voxel 
size 500 µm3 isotropic. QSMs were reconstructed using the COSMOS technique, as 
previously described. 
 
Histology 
Tumor and normal tissues were collected from tumor bearing mice before or at the 
end of in vivo imaging experiments. 10 µm frozen tissue sections were sliced, fixed in 
paraformaldehyde, and stained with hematoxylin and eosin (H&E) or in Perl’s Prussian blue. 
Images of the tissue sections were acquired by scanscope (Aperio). For immunofluorescence, 
antibodies used include rat anti-mouse CD31 (BD, MEC13.3) and goat anti-rat IgG labeled 
with AF350 (Invitrogen). Six different fields of view containing CD31 staining for each 
sample were counted using 25 Chalkley’s random point method over an area of 0.16 mm2 for 
vascularity analysis (Fig. 3d). To quantify the level of staining, three different regions of 
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interest (ROI) with 0.50 mm2 area were sampled for each condition in immunofluorescence 
staining (Fig. 3c) and four ROI with 0.04 mm2 area in each Prussian blue staining (Fig. 4f). 
Specific colors (blue for endothelium and Prussian blue, red for F265S/F292G) were 
extracted and intensities were measured using Image-Pro Plus 6.0 (Media Cybernetics) and 
ImageJ 1.41 (NIH). 
 
Statistical analysis 
Data were expressed as mean ± standard deviation of no smaller than triplicates, and 
analyzed for statistical significance using GraphPad Prism 5 (Graphpad Software). Linear 
regression was used to examine the correlation between SPIO measurements by radioactivity 
and QSM (Fig. 2c). One-way ANOVA was used to compare the staining and vascularity 
levels between different tissues, followed by Tukey’s post-hoc test to determine statistical 
significance (Fig. 3c,d). Two-way ANOVA was used to compare the mean responses of 
different nanoparticles to different time points or to different tumors, followed by Bonferroni 
post-hoc test to determine statistical significance (Fig. 4d,f, Fig. 5b, & Fig. 6c,d). 
 
Results 
 
Synthesis and characterization of leukocyte-mimetic nanoparticles 
Selective binding of SPIO nanoparticles to overexpressed ICAM- 1 was conferred by 
surface coating at an optimal density (~100 molecular/particle) with the I domain of LFA-1 
integrin, engineered for high affinity by mutations of F265S/F292G (denoted as F265S/ 
F292G, KD = 6 nM) [18]. Among physiological ligands for LFA-1 such as ICAMs and 
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junctional adhesion molecule (JAM)-1 [21], ICAM-1 is most important in the setting of 
leukocyte adhesion to inflamed endothelium due to its highest affinity to LFA-1 [22], being 
highly inducible over basal low level expression, and localized expression upon 
inflammatory signals [16,23]. In order to fine-tune coating density of F265S/F292G and 
present targeting moiety in a most functional orientation, oleic acid-capped SPIO 
nanocrystals (Ocean Nanotech) were encapsulated with a layer of phospholipid consisting of 
80% n-poly(ethylene glycol) phosphatidylethanolamine (DPPE-PEG) and 20% dioleoyl-
glycero-succinyl-nitrilotriacetic acid (DOGS-NTA) (Fig. 1a). DOGS-NTA was used for non-
covalent conjugation of targeting moieties with His tag in a robust and reproducible manner 
via high affinity binding to nickel ions chelated by NTA (Ni-NTA) [17,24]. DPPE-PEG was 
included to maintain solubility, stability, and for its low immunogenicity and non-specific 
binding to cells and tissues in vivo [25]. Transmission electron microscope (TEM) images 
revealed monodispersed SPIO nanocyrstals with an outer layer of micelle-like structure (Fig. 
1b; dark ring density corresponds to uniformly distributed nickel ions (the black arrow in top 
right) and diffuse dark density to His-tagged proteins attached to Ni-NTA (the white arrow in 
bottom right)). Hydrodynamic size of SPIO with or without protein conjugation was 
measured to be 60 ± 10 nm by dynamic light scattering (DLS), an increase from 15 nm 
diameter SPIO core mainly due to the addition of phospholipid and PEG. 
Prior to detecting ICAM-1 with nanoparticles, we first examined by 
immunofluorescence flow cytometry (Fig. 1c) and fluorescence microscopy (Fig. 1d) soluble 
I domain (labeled with Alexa Fluor 488 (AF488), Invitrogen) binding to ICAM-1 expressed 
in monolayer culture of cervical cancer cells (HeLa). Specific binding to ICAM-1 was 
detected with the F265S/F292G, which was inhibited by unlabeled F265S/F292G.  
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Figure 1. Synthesis, characterization, and in vitro delivery of leukocyte-mimetic 
nanoparticles. (a) A schematic diagram of iron oxide nanocrystals encapsulated into a 
micelle-like layer composed of amphiphilic phospholipid copolymers (stage I-II) and 
subsequent protein conjugation for molecular targeting (stage III). (b) Uniformly sized, 
monodispersed SPIO with 15 nm core revealed by TEM. A close up view on top 
demonstrates a dark halo corresponding to nickel ions (black arrow) chelated by NTA groups 
surrounding SPIO. On the bottom is the negative staining of protein-conjugated SPIO with 
proteins and PEG groups darkly stained (white arrow), in contrast to a brighter phospholipid 
layer. (c) Flow cytometry measurements of HeLa cells stained with different I domains (10 
μg/ml) labeled with AF488. Non-stained HeLa cells are shown in grey shaded histograms. In 
a competition assay, non-labeled I domains were used at 50 μg/ml. (d) Shown in green is 
immunofluorescence staining of ICAM-1 in HeLa cells using F265S/F292G labeled with 
AF488. Nuclei staining by DAPI is shown in blue. (e) Flow cytometry measurements of 
HeLa cells stained with nanoparticles (25 μg/ml of SPIO and 10 μg/ml of I domains) 
conjugated with different I domains. Non-labeled I domains as a competitor were used at 50 
μg/ml (f) ICAM-1 dependent internalization of SPIO into HeLa cells was confirmed with 
confocal fluorescence microscopy and Perl’s Prussian blue staining. 
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In contrast, no significant binding was observed with the wt I domain (KD = 1.7 mM) [22] 
and the I domain containing a mutation of D137A [17], which disrupts the metal-ion 
dependent adhesion site (MIDAS) and abolishes ICAM-1 binding. The level of nanoparticle 
binding coated with the I domain variants was overall in good agreement with the soluble I 
domain binding, which varied in order from highest to lowest, F265S/F292G, wt, and D137A 
(Fig. 1e). Markedly, specific binding of SPIO conjugated with F265S/F292G (abbreviated as 
Leukocyte-Mimetic Nanoparticle or ‘LMN’) was not inhibited by competition with soluble I 
domain, presumably due to multivalent interaction between nanoparticles and HeLa cells. 
Enhanced binding due to avidity effect was also observed in the binding of nanoparticle 
coated with the wt I domain to HeLa, which resulted in greater binding than with the free wt 
I domain. ICAM-1-mediated binding of LMN but not with the nanoparticles coated with 
D137A (abbreviated as Non-Targeted Nanoparticle or ‘NTN’) led to significant cell surface 
labeling and internalization into the cells, evidenced by fluorescence microscopy and Perl’s 
Prussian blue staining (Fig. 1f). 
 
Quantitative measurement of selective binding of LMN by MRI 
SPIO nanoparticles are being used in clinics as T2* negative contrast agent for MRI. 
In order to validate SPIO as MRI contrast agent as well as to test the accuracy of our MRI 
technique for quantitative mapping of SPIO [19], 3H-labeled phospholipid was additionally 
incorporated into the outer phospholipid layer of SPIO. When HeLa cells were incubated 
with LMN for 4 h at 37 °C, an increase in concentration led to an increase in cellular uptake 
of nanoparticles, reaching a plateau at 450 ng/106 cells (Fig. 2a). LMN delivery was specific 
to ICAM-1 expression, evidenced by little accumulation into HeLa with NTN and much  
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Figure 2. Quantitative measurement of selective binding of SPIO to ICAM-1 by MRI. (a) 
The amount of SPIO internalized into HeLa or 293T was measured by radioisotope 
measurement of 3H-phospholipid incorporated into SPIO nanoparticles. SPIO nanoparticles 
were coated with either F265S/F292G (LMN) for ICAM-1 targeting or with D137A (NTN) 
as a control. (b) T2* and susceptibility images of agarose-embedded HeLa cells that were 
labeled with 200-0 μg/ml of LMN. (c) A comparison of iron mass estimated by QSM 
technique and radioisotope measurement. Shown are the measurements of agarose-embedded 
free LMN (closed circles) and LMN internalized into HeLa cells (closed circles). 
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lower delivery with LMN into 293T, a cell line with no or little expression of ICAM-1. HeLa 
cells with known amount of internalized LMN by 3H-radioisotope decay were then 
embedded into agarose and scanned with a MRI scanner. As expected, T2* showed a 
decrease in magnitudes with an increase in the amount of SPIO (Fig. 2b). With quantitative 
susceptibility mapping (QSM) algorithm was observed a close agreement with ~30% 
standard deviation from direct radioactivity measurements of free or intracellular SPIO, 
highlighting the ability of QSM in detecting as low as 1 µg accumulation into 100 µl in 
volume (Fig. 2c). 
 
Ex vivo detection of ICAM-1 induction in human tumor xenograft and in inflamed stroma 
Not only is ICAM-1 upregulated in several carcinomas compared to respective 
normal epithelium, implicating active involvement of ICAM-1 in cancer development, its 
induction has also been observed in tumor vasculature caused by an inflamed network 
encompassing tumor and tumor microenvironment [26-28]. Previously, we have found that 
human LFA-1 I domain cross-reacted with murine ICAM- 1 [17], which was recapitulated by 
the staining of ICAM-1 induced in murine brain endothelium (b.End3) after 
lipopolysaccharide (LPS) treatment (Fig. 3a). When tissue sections of GFP-expressing HeLa 
xenograft were analyzed for ICAM-1 detection by soluble F265S/ F292G labeled with 
AF594 (Invitrogen), most of the GFP signal was overlapped with red fluorescence (Fig. 3b). 
Notably, we found that the majority of endothelial cells (PECAM-1 (CD31) positive) within 
the tumor were also stained by F265S/F292G. In contrast, the level of ICAM-1 induction and 
colocalization with CD31 staining in the vasculature away from the tumor, such as those in 
the skin, was far lower, amounting to ~15% compared to 70% and 35% of the vasculature  
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Fig. 3 (continued) 
 
 
Figure 3. Ex vivo molecular imaging of tumor and tumor-associated vasculature. (a) 
Confocal fluorescence images of murine b.End3 cells before and after LPS treatment and 
HeLa cells stained with murine (top) and human (bottom) I domains (F265S/F292G) labeled 
with AF594. Nuclei staining by DAPI is shown in blue. (b) Immunofluorescence images of 
GFP-expressing HeLa xenograft tumor tissue costained with F265S/F292G-AF594 and anti-
murine CD31 antibodies. Skin tissues from non-tumor bearing mice were used as control. (c) 
The percentages of endothelium costained with CD31 and F265S/F292G within the tumor, in 
the periphery (300 µm from the tumor), and in the skin were determined from 
immunohistology (n = 6). (d) Vascularity within the tumor, in the periphery (300 µm from 
the tumor), and in the skin was quantified using Chalkley’s method (25 random points per 
field of view) (n = 3; *p < 0.05, **p < 0.01). 
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within the tumor and its periphery (defined as a region within 300 µm distance from the edge 
of tumor), respectively (Fig. 3b-d). 
 
In vivo detection of ICAM-1 induction in human tumor xenograft and in inflamed stroma 
After confirming specific detection of ICAM-1 in ex vivo tumor slice by free 
F265S/F292G, we then examined if systemically-delivered nanoparticles would accumulate 
to the tumor and inflamed stroma by ICAM-1 targeting. To validate that nanoparticle 
localization is ICAM-1 specific and not due to an increased permeability of the tumor 
vasculature, NTN and ICAM-1 negative 293T cell xenograft were used as controls. The 
growth of HeLa and 293T xenograft in mice was confirmed by whole body imaging of GFP 
(Fig. 4a). At 50 h after intravenous injection of nanoparticles, whole body imaging of near-
infrared (near-IR) fluorescence (AF750 attached to the I domains) indicated accumulation of 
LMN into HeLa but much less into 293T xenograft (Fig. 4a,b). Subsequent ex vivo imaging 
of the tumor and the major organs harvested from the mice further confirmed a greater level 
of delivery into HeLa xenograft with LMN (Fig. 4c). The signal from the kidney was by far 
greater than those from other organs both for LMN and NTN, indicating ICAM-1 
independent clearance through the kidney (Fig. 4c). Interestingly, higher fluorescence was 
also detected in the liver with LMN, presumably caused by persistent, low level 
inflammation in the liver. Whole body imaging of nanoparticles localized to HeLa and 293T 
xenograft over the time course of 30 min-50 h post-injection showed that the peak 
accumulation occurred at 1-3 h post-injection, followed by a gradual decrease over 3 days 
and a complete clearance by 7 days (Fig. 4d). The presence of LMN into HeLa was also 
confirmed by direct staining of iron with Prussian blue (Fig. 4e,f). To map the distribution of  
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Figure 4. In vivo molecular imaging of tumor and tumor-associated vasculature. In vivo (a, 
b) and ex vivo (c) near-IR imaging of mice at 50 h after intravenous injection of NTN vs. 
LMN. GFP indicates the growth of HeLa (‘1’) and 293T (‘2’) tumors. The distribution of 
nanoparticles into the major organs (‘3’-‘8’) were also examined. (d) Near-IR fluorescence 
intensities of HeLa and 293T tumors at different time points after intravenous injection of 
LMN vs. NTN (n = 4; **P < 0.01, ***p < 0.001). (e) Perl’s Prussian blue staining of tumor 
sections collected at 50 h after the injection of LMN vs. NTN. Stained iron is marked with 
black arrows. (f) Percentage of cells stained in Prussian blue (top) and the intensity of 
Prussian blue in the field of view (bottom) within tumor sections (n = 3; ***p < 0.001 
between LMN vs. NTN in Hela tumor. †††p < 0.001 between HeLa and 293T tumor using 
LMN). (g) Immunofluorescence imaging of tumors at 4 h post-injection of LMN. Tumor 
sections were also stained with anti-CD31 antibody for delineating vasculature. LMN 
localization into the tumor vasculatures was indicated with white arrows. (h) Fluorescence 
imaging of tumors at 4 h post-injection of NTN. 
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LMN by fluorescence microscopy, SPIO nanoparticles conjugated with AF594-labeled I 
domains were intravenously injected into the mice with HeLa/293T xenograft. When the 
xenograft tissue was examined 4 h after nanoparticle injection, specific accumulation of 
LMN into HeLa tumor was observed, judging from colocalization between GFP expression 
in HeLa and AF594 fluorescence (Fig. 4g,h). Importantly, consistent with the detection of 
ICAM-1 in the tumor vasculature by direct staining of the tissue (Fig. 3b), a high percentage 
of CD31 positive cells in HeLa as well as in 293T xenografts were also targeted by LMN. 
The localization of ICAM-1 specific nanoparticles within the tumor-associated vasculature, 
therefore, was likely responsible for higher signals detected within 293T xenograft at earlier 
time points (Fig. 4d), despite the fact that 293T itself exhibited almost no binding of LMN 
(Fig. 4e,f). This finding highlights a potential use of LMN for detection of tumor growth by 
their accumulation into inflamed tumor vasculature, irrespective of the type of tumor surface 
antigen. 
 
In vivo detection of temporal dynamics of inflammation by optical imaging and MRI 
In order to further confirm that our leukocyte-mimetic nanoparticles sensitively detect 
the induction of ICAM-1 not only due to an inflammatory milieu in the tumor but also by 
acutely induced inflammation, we imaged mice after subcutaneous (Fig. 5) or intravenous 
injection of LPS (Fig. 6). Temporal mapping of nanoparticle distribution demonstrated a 
greater localization of LMN into the LPS injection site over PBS injection site as a control, 
peaking at 12 h post-injection of LPS and gradually decaying over 72 h (Fig. 5a,b). Higher 
accumulation into the liver was also observed with LMN, attributed to the inflammatory 
response induced by the leakage of locally injected LPS into circulation. We also observed a 
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rapid increase in fluorescence in the bladder, irrespective of targeting moieties, attributed to 
renal clearance of some fraction of proteins dissociated from nanoparticles. Interestingly, 
NTN accumulated more into the LPS site than into the PBS site, presumably due to non-
specific phagocytosis of nanoparticles by immune cells. Selected mice treated with systemic 
delivery of 100 µg LMN were then subjected to MRI after whole body optical imaging to 
demonstrate that our nanoparticles could be used for quantitative detection of inflammation 
by a clinically relevant imaging technique (Fig. 5c). T2* magnitude images identified the 
presence of LMN in the LPS injection site as darkness, which could be confused with other 
dark regions. QSM revealed the accumulation of ~0.3 µg of iron oxide (corresponding to 
detection of less than 1% of injected dose) into the LPS injection site, colocalized with the 
site identified by near-IR imaging (Fig. 5a). 
In response to systemic inflammation caused by intravenous injection of LPS for 12 h 
prior to nanoparticle (~200 µg) injection, optical mapping of nanoparticle distribution 
demonstrated greater localization of LMN in the liver compared to that of NTN in mice (Fig. 
6a,c), peaking at 1h post-injection of nanoparticles and subsequently diminishing at later time 
points. The level of delivery overall was higher with LPS even with NTN, indicating some of 
nanoparticles accumulated into the liver was caused by ICAM-1 independent phagocytosis. 
After optical imaging, mice were transcardially perfused with PBS for MRI, which would 
have removed nanoparticles retained in the blood pool in the liver. Temporal mapping of 
SPIO distribution using MRI QSM measured about 20% of the total dose of LMN was 
specifically uptaken by the liver 1 h post-injection due to LPS-induced inflammation (Fig. 
6b,d and supplementary videos). QSM quantification also demonstrated a similarly greater 
localization of LMN into the liver under acute inflammation at different time points, 
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Figure 5. In vivo molecular imaging of subcutaneous acute inflammation using near-IR 
camera and MRI. (a) In vivo near-IR whole body imaging of LMN vs. NTN distribution in 
mice 1 h after nanoparticle injection. Mice were exposed to LPS (‘1’) and PBS (‘2’) for 3, 
12, 24, or 72 h at the time of nanoparticle delivery. (b) Fluorescence intensities of LMN at 
LPS vs. PBS injection sites were shown (n = 3; **p < 0.01, ***p < 0.001 between LPS and 
PBS site at specific time points; †p < 0.05 between 12 h and 72 h at LPS site). (c) T2* 
magnitude and susceptibility mapping images of nanoparticle distribution in mice at 4 h after 
nanoparticle injection. Mice were exposed to LPS/PBS for 12 h at the time of nanoparticle 
injection. Bright spot identified by susceptibility mapping as the accumulation of SPIO was 
indicated with crosshair. 
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Figure 6. In vivo molecular imaging of systemic acute inflammation using near-IR camera 
and MRI. In vivo near-IR whole body imaging (a) or MRI (b) of LMN vs. NTN distribution 
in mice at 1, 8, 25 h post-injection of nanoparticles in mice exposed to systemic LPS for 12 h 
or control mice with no treatment. LMN vs. NTN distributions into the liver were quantified 
by near-IR optical imaging (c) and MRI (d) (n = 3; *p < 0.05, ***p < 0.001 between LMN 
vs. NTN at specific time points). 
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exhibiting qualitative agreement with the temporal mapping using optical imaging (Fig. 
6b,d). Discrepancy between optical intensity and QSM was unavoidable as MRI was 
performed after perfusion of the mice as well as due to the different kinetics of degradation 
for fluorescence dye (AF750) and SPIO. 
 
Discussion 
 
Sensitive detection of inflammation will be of high significance for diagnosis of 
diseases caused directly by host inflammatory response such as sepsis, allograft rejection, 
lupus, as well as those that are influenced by inflammation such as cardiovascular disease 
and cancer. In this study, we designed MRI-compatible SPIO nanoparticles, and 
demonstrated a successful detection of constitutive expression of ICAM-1 in tumor, as well 
as ICAM-1 induction in tumor-associated vasculature, where tumor growth and angiogenesis 
are active. Prior approaches to inflammation detection have been largely based on antibodies 
that are against cell adhesion molecules such as ICAM-1 and VCAM-1 [8-13,29], lacking in 
the ability to fine-tune affinity and avidity of targeting moieties on nanoparticles that are 
critical to inflammation-specific targeting. From our previous in vitro studies [17,24], we 
have demonstrated specific localization into inflamed but not to resting endothelium and 
immune cells of nanoparticle (50-100 nm in diameter) coated with integrin LFA-1 I domain 
engineered for high affinity to ICAM-1. Furthermore, combining recently developed 
quantitative susceptibility mapping technique, we quantified sub-microgram quantity of iron 
oxide accumulated in both ICAM-1-expressing cell phantom in vitro and acute inflammation 
induced by LPS in vivo, corresponding to less than 1% of injected dose. 
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Despite the fact that ICAM-1 is basally expressed in all endothelium [16,23] and 
therefore the notion that ICAM-1 may not be a suitable target for inflammation, our studies 
emphasize selective delivery by targeting molecules that are induced greatly under 
inflammation [30,31]. Nanoparticles of ~100 nm will experience hydrodynamic force 
generated by the blood flow [32,33], such that there should be sufficient simultaneous 
molecular interactions with the cells for nanoparticles to remain on cell surface. The number 
of minimum molecular interactions required for stable adhesion of nanoparticles will also 
depend on the adhesion strength of each interaction. Therefore, specificity toward high 
ICAM-1 site will be influenced by the affinity of molecular interaction and the valency 
between nanoparticles and target cells, where the design of nanoparticles to permit tunable 
affinity and avidity of physiological interaction is of significant advantage. Our nanoparticles 
to a great extent mimic the behavior of activated leukocytes, which would adhere much 
better to inflamed endothelium. 
Increasing number of studies has begun to focus on the crosstalk between the immune 
activation of vascular niche, angiogenesis, and tumor progression [34,35]. Upregulated levels 
of ICAM-1 in tumor have been linked to two different contexts, one serving as a marker for 
the recruitment of effector immune cells and tumor killing [36], while it was also observed in 
malignant and metastatic tumors with poor prognosis [37]. Seemingly contradicting roles of 
ICAM-1 may be due to the complexity of inflammation in various phases of tumor 
development, which can be better examined by in vivo imaging tools. Our nanoparticles did 
indeed show the localization into the tumor vasculature, while their localization into the 
vasculature elsewhere was non- detectable. With human tumor xenograft model, we observed 
that the majority of tumor mass was comprised of tumor cells with poor vascularity present 
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therein. Higher vascularity was found in the periphery of the tumor, often called the invasive 
tumor front, where ICAM-1 overexpression associated with higher immune activity has also 
been reported in many carcinoma cases [27,38-41]. Notably, we have demonstrated that 
intravenously injected nanoparticles targeting ICAM-1 specifically localized into the 
vasculature associated with the tumor progression. With further improvement of detection 
sensitivity in addition to more native tumor models containing not only tumor cells 
themselves but also fully-developed vasculatures and other stroma cells such as 
macrophages, our nanoparticles may provide a universal tumor imaging strategy not by 
tumor surface markers limited to specific cancer types but by the inflamed microenvironment 
which is associated with almost all cancer development. 
Besides sensitive detection of chronic inflammation implicated in cancer, prompt and 
accurate detection of acute inflammation induced by bacterial or viral infection such as sepsis 
is also of clinical importance. Acute inflammation dramatically induces ICAM-1 induction 
not only in endothelium but also in immune cells, such that both cellular components become 
the targets by I domain-coated nanoparticle. Using LPS-induced acute inflammation model, 
we demonstrated optical imaging of the temporal dynamics of inflammation. Specific 
localization of LMN was also confirmed by QSM technique using MRI. The degree of 
localization of ICAM-1 targeting nanoparticles into an inflamed site will closely reflect 
different phases of inflammation, from the onset of inflammation to resolution phase. 
Therefore, quantitative prediction of spatiotemporal distribution of nanoparticles may 
provide critical information on diagnosis and the choice of therapy regimen in clinics. 
In summary, our ICAM-1 targeting strategy by mimicking the behavior of leukocytes 
in their ability to localize to the inflamed endothelium was able to detect ICAM-1 
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overexpression in tumor cells, tumor vascular microenvironment, and acute inflammation. In 
the design of ICAM-1 targeting nanoparticles by conjugation with LFA-1 I domain, we 
employed His-tag binding to nickel-NTA, which we previously found [17] to be critical in 
order to fine-tune the coating density of targeting moieties to be specific to ICAM-1 
overexpression but not to basally present ICAM-1. The idea of optimizing molecular 
interactions by tuning the avidity between ligands and receptors could provide a useful 
strategy to molecular targeting of some important targets that are basally expressed 
elsewhere. Inflammation-targeting nanoparticles with the lipid layer shell can also be used to 
carry small, hydrophobic drugs, achieving simultaneous imaging and targeted drug delivery. 
 
Conclusion 
 
This study presents physiology-inspired design of SPIO nanoparticles for in vivo 
detection by optical imaging and MRI, mimicking activated leukocyte in its ability to 
recognize inflamed endothelium. Nanoparticles in vivo will experience hydrodynamic force 
induced by the blood flow, requiring simultaneous molecular interactions with sufficient 
adhesion strength with the cells for nanoparticles to remain on cell surface. Therefore, the 
design of nanoparticles with tunable affinity and avidity of physiological interactions would 
be critical to selectivity and efficiency of leukocyte-mimetic nanoparticles in targeting 
inflammation. Notably, we observed specific accumulation of systemically-delivered 
nanoparticles into the vasculature within the tumor and invasive tumor front where the tumor 
growth and angiogenesis were active, while their localization into the vasculature elsewhere 
was much lower. The use of two different nanoparticles differed only by the type of I 
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domains (active vs. inactive) as targeting moieties against ICAM-1 enabled us to 
discriminate inflammation-driven accumulation into the tumor microenvironment from 
passive distribution, which may result from the leakiness of the vasculature within the tumor. 
Inflammation-targeting nanoparticles such as SPIO with the layer of phospholipid are also 
suitable for carrying small molecule drugs, achieving simultaneous imaging and targeted 
drug delivery. 
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CHAPTER 4 
 
VIRUS-MIMETIC POLYPLEX PARTICLES FOR SYSTEMIC AND 
INFLAMMATION-SPECIFIC TARGETED DELIVERY OF LARGE 
GENETIC CONTENTS 
 
Abstract  
 
Systemic and target-specific delivery of large genetic contents has been difficult to 
achieve. Although viruses effortlessly deliver kilobase-long genome into cells, its clinical use 
has been hindered by serious safety concerns and the mismatch between native tropisms and 
desired targets. Nonviral vectors, in contrast, are limited by low gene transfer efficiency and 
inherent cytotoxicity. Here we devised virus-mimetic polyplex particles (VMPs) based on 
electrostatic self-assembly among polyanionic peptide (PAP), cationic polymer 
polyethyleneimine (PEI) and nucleic acids. We fused PAP to the engineered ligand-binding 
domain of integrin aLb2 to target intercellular adhesion molecule-1 (ICAM-1), an inducible 
marker of inflammation. Fully assembled VMPs packaged large genetic contents, bound 
specifically to target molecules, elicited receptor-mediated endocytosis and escaped 
endosomal pathway, resembling intracellular delivery processes of viruses. Unlike 
conventional PEI-mediated transfection, molecular interaction- dependent gene delivery of2 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
This chapter is modified and reprinted from, Kang S, Lu K, Leelawattanachai J, HuX, Park S, Park T, Min IM, 
and Jin MM. Virus-mimetic polyplex particles for systemic and inflammation-specific targeted delivery of large 
genetic contents. Gene Therapy 2013;20:1042-1052, with permission from the publisher. Leelawattanachai J 
developed and optimized the conditions for homogenous electrostatic self-assembly of VMPs, performed 
validation assays, and wrote the manuscript related to the assembly method and validation. 
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VMPs was unaffected by the presence of serum and achieved higher efficiency without 
toxicity. By targeting overexpressed ICAM-1, VMPs delivered genes specifically to inflamed 
endothelial cells and macrophages both in vitro and in vivo. Simplicity and versatility of the 
platform and inflammation-specific delivery may open up opportunities for multifaceted gene 
therapy that can be translated into the clinic and treat a broad range of debilitating immune 
and inflammatory diseases. 
 
Introduction 
 
Viruses have evolved ways to efficiently deliver their genetic materials into cells that 
can be as large as multiples of kilobase-long nucleic acids. The use of viral gene delivery 
vectors for clinical applications [1–5], however, poses serious safety issues, including 
pathogenicity by insertional mutagenesis [6] and anaphylactic response to the virus [7, 8]. On 
the other hand, synthetic nonviral vectors suffer from inherent cytotoxicity and are severely 
limited due to low gene transfer efficiency in systemic parenteral applications. Particularly, 
cationic nonviral vectors, which can disrupt the integrity of plasma membrane during entry 
into cells [9, 10], are easily inactivated by negatively charged molecules such as 
glycosaminoglycans in circulation [11–13]. 
To achieve cell type- or cell state-specific targeted systemic delivery, it often requires 
the use of complex molecules such as antibodies and proteins that specifically bind to target 
molecules. However, systemic site-directed delivery of large nucleic acid molecules has met 
limited success. In fact, studies have been mostly constrained to the delivery of small nucleic 
acids, such as siRNA [14–17]. Although viruses possess the ability to overcome many 
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barriers of gene delivery such as cell entry through the membrane and escape from lysosomal 
nuclease degradation, engineering the tropism of viral vectors for site-directed delivery to a 
range of different targets [18–20] has been challenging. Nonviral vectors are capable of 
delivering large content of nucleic acids such as plasmids, but modifications to confer 
specific targeting have been mostly confined within chemical/covalent attachments of small 
molecules [21], peptides [22] and several types of proteins [23, 24], which would inevitably 
affect the original physicochemical properties of the vectors. 
In this study, we devised a polyanionic peptide (PAP) comprised of 18 randomly 
ordered glutamic and aspartic acids that can be expressed as a fusion to proteins to mediate 
electrostatic attachment to cationic transfection agents. Polyethyleneimine (PEI) was used as 
a scaffold to hold both a large content of nucleic acid and PAP-fused targeting moieties. PEI 
has been extensively studied as a cationic polymer-mediated gene delivery agent and has 
been considered to have relatively high gene transfer efficiency [25–29]. PEI has all primary, 
secondary and tertiary amines, providing buffering capacity at low pH of late endosomes 
[30]. This promotes an influx of counter-ions such as chloride [31], raising osmotic pressure 
that eventually bursts the vesicles and releases nucleic acid payload, which has been termed 
as the proton sponge effect [32]. 
To achieve targeted gene delivery to inflammatory diseases, we fused the PAP to the 
major ligand-binding domain (I domain) of integrin lymphocyte function-associated antigen-
1 (LFA-1; aLb2) as a targeting moiety. The physiological counter receptor for LFA-1 is the 
intercellular adhesion molecule-1 (ICAM-1), which is highly expressed on inflamed cell 
surfaces [33, 34] that often colocalizes at various disease sites [35, 36]. ICAM-1 is also 
subverted as a receptor for the major human rhinoviruses (HRVs) [37], which gain cell entry 
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by multivalent interaction with ICAM-1 that promotes rapid endocytosis [38, 39]. We have 
previously engineered the I domain into a high-affinity (HA) mutant to ICAM-1 by directed 
evolution [40]. The I domain is a globular Rossmann fold protein of approximately the size 
of a single-chain variable- fragment antibody. We previously used the HA I domain as a 
targeting moiety for various types of carriers to deliver drugs [41, 42] and imaging contrast 
agents [43] specifically to inflamed endothelial cells and immune cells, and to cancer cells 
and their stroma. 
Here we show that, by fusing the PAP to the I domain (PAP-Id) and using a cationic 
nonviral vector PEI, we were able to establish a molecular interaction-dependent gene 
delivery platform based on their stepwise electrostatic self-assembly, which creates virus- 
mimetic polyplex particles (VMPs) that mimic the processes involved in virus infection. 
Similarly as to how cell entry is gained by HRVs, our VMPs were also able to mediate 
cellular endocytosis by clustering ICAM-1 via multivalent binding of the I domains. Because 
the attachment of targeting moieties is a self-assembling process, we were able to precisely 
control the moiety density or avidity, optimal for efficient endocytosis and gene transfer. Not 
only did the association of DNA and PEI particles with PAP-Id reduce the inherent 
cytotoxicity of PEI, it also enabled the delivery to be unaffected by the presence of serum. 
Similarly as acid-catalyzed conformational change in HRV capsid leads to penetration of the 
membrane, VMPs escaped endosomal degradation and led to efficient gene expression. 
Moreover, by targeting ICAM-1, we were able to deliver genes specifically to inflamed 
endothelial cells and immune cells both in vitro and systemically in vivo. 
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Materials And Methods 
 
Cell culture conditions  
HeLa, bEnd.3, RAW 264.7 (ATCC, Manassas, VA, USA) and primary mouse lung 
cells were cultured in Advanced Dulbecco’s modified Eagle’s medium (Invitrogen, Carlsbad, 
CA, USA) containing 2 mM L-glutamine, Pen-step (100 units/ml penicillin and 100 µg/ml 
streptomycin) and 10% fetal bovine serum (FBS; endotoxin free, PAA Laboratories, 
Piscataway, NJ, USA). Primary mouse lung cells were harvested from fetus lungs of mouse 
strain Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo (Jackson Laboratory, Bar Harbor, ME, USA). 
Lungs were aseptically minced and digested in 1 mg/ml collagenase A (Roche, Basel, 
Germany) for 3 h at 37 °C, which were then filtered through 70-µm nylon mesh cell strainer 
and washed twice in complete media for culture. HMEC-1 (Center for Disease Control, 
Atlanta, GA, USA) was propagated in MCDB 131 medium (Invitrogen) supplemented with 
10% FBS, 10 mM L-glutamine, Pen-strep, 1 µg/ml hydrocortisone (MP Biomedicals, Solon, 
OH, USA) and 10 ng/ml human epidermal growth factor (Invitrogen). THP-1 cells (ATCC) 
were cultured in RPMI 1640 medium (Invitrogen) with 10% FBS and Pen-strep. Endothelial 
cells and primary mouse lung cells were trypsinized at confluency and washed to remove 
residual trypsin before plating. All mammalian cells were maintained at 37 °C in a 5% CO2 
humidified incubator. 
 
Protein construction, design, and purification 
Wild-type LFA-1 I domain sequence (Asn-129 to Tyr-307) followed by a stop codon 
was subcloned into pET28a vector (Novagen, Madison, WI, USA) between BamH1 and 
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Xho1. QuickChange (Stratagene, La Jolla, CA, USA) site-directed mutagenesis was used to 
create F265S/F292G and D137A mutants. For GFP-Id, a superfolder GFP was inserted 
between Nhe1 and BamH1. To construct PAP-Id, complementary primers encoding 50 -
ctagcgaggatgaagatgaggaagacgaagaagatgaagaggacgaagaggacgaggatg-30 and 50 -
gatccatcctcgtcctcttcgtcctcttcatcttcttcgtcttcctcatcttcatcctcg-30 were annealed and directly 
ligated between Nhe1 and BamH1. Constructs were transformed into Escherichia coli, BL21 
(DE3) cells (Novagen) for production of the fusion proteins. Overnight starter culture was 
used to inoculate a larger Luria Bertani medium at 1:40 volume ratio and was grown at 37 °C 
to OD600 of 0.4–0.5 (~2 h). Then cells were induced with freshly prepared 1 mM isopropyl-
b-D-thiogalactopyranoside at 25 °C overnight (~15 h). Cells were recovered by 
centrifugation and sonicated in buffer A (50 mM NaH2PO4, 300 mM NaCl, 10 mM 
imidazole, protease inhibitor cocktail (ProteCEASE-EDTA free, G-Biosciences, St. Louis, 
MO, USA)) with pH adjusted to 8.0 for GFP-Id and 6.0 for PAP-Id. Soluble fraction of GFP-
Id was purified by passage over a Ni-NTA column (Pierce, Rockford, IL, USA). Insoluble 
fraction of PAP-Id was washed in buffer A with four cycles of sonication and super-
centrifugation at 20,000 g for 30 min. Protein pellet was then solubilized in buffer B (buffer 
A plus 6 M guanidine HCl, pH 8.0) and purified by Ni-NTA. GFP-Id and PAP-Id were 
washed in buffer C (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH 8.0) and then 
eluted in buffer D (50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, pH 8.0). Eluted 
proteins were then subjected to gel filtration chromatography using Superdex S200 column in 
phosphate-buffered saline (PBS) connected to AKTA Purifier (GE Healthcare, Pittsburgh, 
PA, USA). 
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Electrostatic self-assembly of VMPs  
For any given mass ratios, plasmid and PEI (branched, MW 25,000, Sigma- Aldrich, 
St. Louis, MO, USA) were each diluted in one volume of PBS (pH 7.4) and PAP-Id in two 
volumes of PBS. Solutions containing plasmid and PEI were first vortex mixed and 
incubated at room temperature for 40 min. Plasmid/PEI mixture was then gently mixed with 
PAP-Id solution and incubated at room temperature for 40 min. Vector for GFP expression 
(pGFP) was constructed by subcloning a complete Kozak consensus sequence and enhanced 
GFP sequence followed by a stop codon between EcoRI and BglII of pAAV-MCS vector 
(AAV Helper-Free System, Agilent Technologies, Santa Clara, CA, USA). Vectors for 
expression of diphtheria toxin A (pDTA) and Cre recombinase (pCRE) were obtained from 
Addgene (Cambridge, MA, USA), originally named as PGK-DTA-bpA (plasmid 13440) and 
pLOX-CW-CRE (plasmid 12238), respectively. All components used for assembly of VMPs, 
including plasmids, PAP-Id, PEI and PBS, were filter sterilized through 0.2-µm centrifugal 
or syringe filters before assembly. 
 
Dynamic light scattering and zeta-potential measurements of VMPs 
The size distribution and zeta-potential of VMPs were determined using Zetasizer 
Nano ZS (Malvern Instruments (Malvern, Worcestershire, UK)). VMPs prepared with 1 µg 
of plasmid and the relative mass of PEI and/or PAP-Id were each diluted in 750 µl of PBS 
(pH 7.4). The solution was added to the cell and the measurements were carried out at 25 °C. 
 
In vitro delivery of VMPs  
 101 
 Cells were grown in 24-well plates to confluence and pretreated with complete media 
containing 1 µg/ml of LPS (E. coli, 026:B6, Sigma) to induce inflammation. Each well 
received VMPs prepared with 0.4 µg of plasmid and the relative mass and volumes of PEI 
and PAP-Id. Final VMPs were then mixed with an equal volume of FBS and incubated at 
room temperature for 40 min before delivery to cells. After delivery, cells were washed twice 
with media, followed by addition of fresh complete media. 
 
In vivo delivery of polyplex particles 
Eight-to-ten-week-old female BALB/c mice (Jackson Laboratory) were used. All 
administrations performed in this study were given intravenously, using 29G × 0.5” insulin 
syringes via lateral tail vein route injections. To induce systemic inflammation, 20 µg per 
mouse of LPS (E. coli, 026:B6, Sigma) in PBS (pH 7.4) was injected. VMPs bearing 5 µg of 
plasmid was formed in a mass ratio of the components (plasmid:PEI:PAP-Id) fixed to 1:6:16 
in a final volume of 200 µl. All animal procedures were approved by the Cornell University 
IACUC and were conducted in accordance with recommendations in the Guide for the Care 
and Use of Laboratory Animals published by the National Institutes of Health. 
 
Immunofluorescence for imaging and flow cytometric analysis  
Mean fluorescence intensity and percentage of GFP-positive cells were quantified by 
flow cytometry (Beckman Coulter EPICS XL-MC, Brea, CA, USA). After in vitro delivery 
of VMPs for GFP expression, cells were trypsinized, washed with washing buffer (PBS, 
0.5% bovine serum albumin, pH 7.4) and subjected to flow cytometer. Total fluorescence 
was quantified by lysing cells with 1% (v/v) Triton X-100 in PBS and measuring with a 
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fluorescence plate reader Infinite M1000, TECAN (Männedorf, Switzerland). Confocal 
microscopy (Zeiss LSM 710, Zeiss (Oberkochen, Germany)) was used to assess endocytosis 
of VMPs and protein expression in HeLa cells. PAP-Id was conjugated to Alexa Fluor 555 
(succinimidyl ester, Invitrogen) and pGFP was labeled with Cy5 (Label IT Nucleic Acid 
Labeling Kit, Mirus Bio (Madison, WI, USA)). HeLa cells were grown in 35mm glass 
bottom dishes (0.16–0.19 mm cover glass, In Vitro Scientific (San Jose, CA, USA)) and 
fixed in 3.7% formaldehyde for 1 h at different time points after delivery of fluorescently 
labeled VMPs. Expression of ICAM-1 in mouse lungs were assessed by GFP-Id. Lungs were 
collected at different time points after systemic LPS treatment (20mg per mouse, E. coli, 
026:B6, Sigma) and were minced and digested in 1 mg/ ml collagenase A (Roche) for 3 h at 
37 °C. Singlet lung cells were prepared by passage through 70-µm nylon mesh cell strainer 
and incubation with red blood cell lysis buffer (eBiosciences, San Diego, CA, USA) for 5 
min on ice. Cells were then washed and labeled for ICAM-1 with 10 µg/ml GFP-Id in ice-
cold labeling buffer (PBS, 0.5% bovine serum albumin, 10 mM MgCl2, pH 7.4) for 1 h. Cells 
were then labeled with either rat IgG anti-mouse CD31 (1:20, BD Pharmingen, San Diego, 
CA, USA) or rat IgG anti-mouse F4/80 (1:50, Abcam, Cambridge, UK) for 1 h, followed by 
goat anti-rat IgG-PE (Santa Cruz, Santa Cruz, CA, USA) as secondary antibody for 1 h. For 
detection of GFP expression after delivery of VMPs bearing pGFP, singlet lung cells were 
fixed with 3.7% formaldehyde for 1h and permeabilized with 1% (v/v) Triton X-100 for 30 
min. Permeabilized cells were then labeled with rabbit IgG anti-GFP antibody (1:20, 
Invitrogen) for 1h, followed by goat anti-rabbit IgG-PE (1:100, Santa Cruz) for 1h. Cells 
were then labeled for CD31 and F4/80 similarly as described, followed by goat anti-rat IgG-
FITC (1:100, Santa Cruz) for 1h. 
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Real-time quantitative PCR 
Total RNAs from harvested lungs were extracted using TRI Reagent (Ambion, 
Austin, TX, USA). Briefly, mouse lung tissue (~150mg) was homogenized in 1 ml of TRI 
Reagent solution followed by brief sonication. Homogenized lysates were mixed with 200 µl 
chloroform and centrifuged at 12,000 g for 15 min. In all, 400 µl of colorless upper aqueous 
phase was collected and mixed with 500 µl isopropanol and loaded to spin columns (Zymo-
Spin II, Zymo Research, Irvine, CA, USA). Eluted RNA (1µg) was converted to cDNA using 
a reverse transcription kit (High Capacity cDNA RT kits, Applied Biosystems, Foster City, 
CA, USA) in a thermal cycler (GeneAmp PCR System 2700, Applied Biosystems). Real-
time gene amplification analysis (MyiQ iCycler, Bio-Rad) was performed using a 
quantitative PCR kit (Sybr Green 2 × Master Mix, Bio-Rad, Hercules, CA, USA) to measure 
gene expression of GFP relative to CYC1 housekeeping gene. Primers for GFP were 
previously reported and for CYC1 (NM_025567) were obtained from Mouse qPrimerDepot 
of the National Cancer Institute. 
 
Quantification of cell viability  
Cell viability of HeLa cells treated with VMPs bearing pDTA was analyzed by trypan 
blue exclusion test. Cells were incubated with 0.2% trypan blue for 5 min, and microscopic 
images were taken at random places of culture wells. Viable cells that excluded trypan blue 
and nonviable cells with blue cytoplasm were counted per given image field for analysis. 
Viability measurements presented in Figures 3–5 were quantified by MTT (3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Cells were incubated with 
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basal media containing 0.5 mg/ml MTT for 4 h at 37 °C. Blue formazan products were 
solubilized in dimethyl sulfoxide and quantified by absorbance at 570 nm. 
 
Statistical analysis  
Data were expressed as mean ± s.d. of at least quadruplicate samples. Statistical 
analysis of data was carried out using GraphPad Prism 5; GraphPad Software Inc. (La Jolla, 
CA, USA). Unpaired Student’s t-test was used to determine statistical significance in 
comparison to matching controls. One-way analysis of variance was used to compare mean 
responses among the different groups, followed by Tukey’s post-hoc test to determine 
statistical significance. 
 
Results 
 
Molecular interaction-specific VMPs for targeted gene delivery 
VMPs were designed to mimic the components of non-enveloped viruses (for 
example, HRVs) and their entry into a specific range of host cells (Figure 1a). VMPs were 
assembled in a sequential manner: first PEI and DNA plasmids were mixed together, to 
which proteins were added. The ratio of protein, DNA, and PEI was adjusted so that 
unsaturated positive charges in PEI would assemble with the negatively charged residues 
(PAP) and DNA (Figure 1b). When added to cells with ICAM-1 expression, VMPs that were 
assembled with integrin LFA-1 I domain would cluster ICAM-1 and trigger the cells for 
endocytosis. A decrease in pH in late endosomes would increase the degree of protonation in 
PEI, whereby it attracts counter-ions and bursts the vesicle by proton sponge effect [31, 32]. 
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Escaped plasmid payloads are then transported into the nucleus and leads to the expression of 
encoding genes. 
To visualize VMPs throughout the processes of cell entry, endosomal escape and 
gene expression, we fluorescently labeled plasmids and PAP-Id to track the particles by 
confocal microscopy. We used the I domain engineered for HA with double mutations 
F265S/F292G [40] (denoted as PAP-Id(HA)). We used a plasmid encoding enhanced green 
fluorescent protein (GFP) under cytomegalovirus promoter (denoted as pGFP). VMPs were 
constructed using Cy5-labeled pGFP and Alexa Fluor 555-conjugated PAP-Id(HA) at a mass 
ratio determined to be within an optimal range for delivery (1:6:16 for pGFP:PEI:PAP-
Id(HA); see Figure 2). We then delivered the fluorescently labeled VMPs in the presence of 
serum to HeLa cells, which express a high level of ICAM-1. Cells were fixed at 3, 24 and 48 
h after delivery. At 3 h post delivery, VMPs were found mostly inside cells, confirmed by 
confocal microscopy (Figures 1c and d). PAP-Id(HA) (red) and pGFP (blue) appeared to be 
in complex with each other, evidenced by colocalization of the two in the merged image. At 
24 h post delivery, some cells began to express GFP, which coincided with the observation 
that the components of VMPs appeared to be dissociated from each other. At 48 h, most cells 
expressed GFP, while much of the components of VMPs were no longer detectable. 
PEI/DNA plasmids polyplex without the I domain (PEI:pGFP = 6:1 w/w) exhibited a size of 
169 nm and a zeta potential of + 26 mV. With the addition of the I domain (PEI:eGFP:I 
domain = 6:1:12), VMPs increased in size (245.5 nm) but displayed a reduced zeta potential ( 
+ 20 mV), presumably due to the presence of negatively charged peptides (PAP) fused to the 
I domains. 
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Figure 1. Cell entry, endosomal escape and gene expression of polyplex particles. (a) HRV 
gains cell entry by binding and clustering ICAM-1, which is overexpressed on inflamed cell 
surfaces. Acid-catalyzed conformational change in the viral capsid (violet) penetrates the 
membrane of late endosomes, through which it releases the RNA genome that leads to the 
synthesis of more viruses (green). (b) Self-assembly of VMPs is mediated by stepwise 
electrostatic interactions among negatively charged nucleic acids, positively charged PEI and 
PAP-Id. VMPs similarly gain cell entry by multivalent ICAM-1 clustering-mediated 
endocytosis. A decrease in pH in late endosomes protonates PEI, attracting counter-ions (Cl−) 
and exerting osmotic pressure and eventually bursting the vesicle. Plasmid payloads that 
escaped endosomal nuclease degradation are then transported into the nucleus through the 
nuclear pore complex (NPC), leading to the expression of encoding genes. (c–e) Confocal 
microscopy was used to track intracellular localization of PAP-Id(HA) (high affinity) 
conjugated to Alexa Fluor 555 (red), pGFP labeled with Cy5 (blue) and GFP expression 
(green) in HeLa cells. (c) VMPs were self-assembled at its optimal mass ratio of 
pGFP:PEI:PAP-Id(HA) adjusted to 1:6:16. Cells received VMPs in the presence of serum, 
which then were fixed at time points of 3, 24 and 48 h after delivery. Colocalization of red 
and blue appears in magenta in merged image. Focal plane was set through the middle of 
cells to capture VMPs inside cells. Dotted lines mark the cell boundaries. Bar = 20 µm. (d) Z-
stack confocal images also show localization of VMPs inside HeLa cells at 3, 24 and 48h 
after delivery. Dotted lines indicate the top surface of cells. Bar = 10 µm. (e) Similarly, 
confocal images were taken at 3 h post delivery to assess the uptake of control particles 
(formed with PEI and PAP-Id(HA), PAP-Id(HA) and pGFP or PEI and pGFP). Note that 
focal plane for imaging was set through the middle of cells to visualize only the particles 
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internalized into cells. Bar = 50 µm. (f ) Fluorescence microscope images (top view) of HeLa 
cells at 3 h post delivery are shown (imaged without fixation). PAP-Id(HA), conjugated to 
Alexa Fluor 555 for fluorescent detection, was either assembled with only plasmid or with 
PEI and plasmid. The particles were incubated with HeLa cells in the presence of serum. Bar 
= 50 µm. 
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 Fig. 1 (continued) 
 
 
 
To show that all three components are necessary for gene delivery by VMPs, we 
assembled fluorescently labeled particles with one component omitted (that is, PAP-
Id(HA)/PEI, PEI/pGFP, and PAP-Id(HA)/pGFP) and delivered to HeLa cells in the presence 
of serum (Figure 1e). At 3 h post delivery, the particles that were formed without pGFP (that 
is, PAP-Id(HA)/PEI) were found as small vesicles inside the cells but to a lesser extent than 
fully assembled VMPs. Particles that were assembled without PAP-Id(HA) (that is, 
PEI/pGFP) were sparsely found inside the cells. The mixture without PEI (that is, PAP-
Id(HA)/pGFP), where PAP-Id(HA) would not associate with pGFP and remain as monomers, 
were not found inside the cells (Figure 1e). In order to show that clustering of ICAM-1 is 
necessary for internalization of particles by the cells, we imaged cells without fixation under 
conventional fluorescence microscopy (Figure 1f). The mixture of PAP-Id(HA)/plasmid was 
indeed smoothly distributed over the cell surfaces, which was in contrast to fully assembled 
VMPs appearing as endocytosed intracellular speckles (Figure 1f). As a negative control for 
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the HA I domain, we used the PAP-fused I domain containing a loss-of- function mutation 
D137A [44] (denoted as PAP-Id(D137A)). Particles that were assembled with Id(D137A) 
were neither observed on the cell surface nor inside the cells, proving that it is ICAM-1-
mediated internalization by which our VMPs were delivered inside the cells (images and 
functional data shown throughout Figures 2–6). 
 
Determining optimal ratios of protein, DNA and PEI for efficient gene delivery 
In an effort to assemble VMPs for the highest gene transfer efficiency, we varied the 
mass ratios of individual components and examined the efficiency of gene expression (Figure 
2). With a fixed amount of pGFP, we varied the amount of PEI ranging from 3 to 8 mass 
ratios of PEI to plasmids. To the mixture of pGFP/PEI particles, PAP-Id(HA) or PAP-
Id(D137A) were added at mass ratios varying from 2 to 32 of proteins to plasmids (Figure 
2a). Assembled VMPs were delivered to HeLa cells in the presence of serum. As additional 
controls and for comparison to conventional transfection methods, pGFP/PEI particles were 
used without proteins, both with and without serum (Figure 2a). Gene transfer efficiency was 
assessed by two different assays, that is, total fluorescence measured from cell lysates, and 
mean fluorescence intensity and the percentage of GFP-positive cells measured by flow 
cytometry. Overall, VMPs formulated with the mass ratios of 8–16-fold excess of PAP-
Id(HA) and 5–7-fold excess of PEI over pGFP led to the highest readouts of total 
fluorescence and a percentage of GFP-positive cells (Figure 2a). Higher than optimal ratios 
of I domains mixed with pGFP/PEI resulted in a decrease in delivery efficiency due to the 
inhibition of VMP binding to cells by free I domains occupying available ICAM-1 on cell 
surface. Although VMPs assembled with PAP-Id(HA) produced over 80% GFP-positive  
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Figure 2. Molecular interaction-specific gene delivery of VMPs. (a, b) VMPs were 
assembled with varying mass ratios among the three components: pGFP, PEI and PAP-Id. 
The mass ratio of plasmid to PEI was titrated from 1:3 to 1:8, which were then assembled 
with various mass ratios of PAP-Id(HA) to probe optimal gene transfer efficiency. PAP-
Id(D137A) (no affinity) was used as a negative control as the loss-of-function point mutation 
abrogates the interaction with ICAM-1. (a) Heatmap in green shows the total fluorescence 
measured by a fluorescence microplate reader after cell lysis (n = 4), in yellow shows the 
mean fluorescence intensity measured by flow cytometry (n = 4) and in white is the 
percentage of GFP-positive cells as compared with non-transfected control cells (n = 4). 
Fluorescence values are shown in relative fold difference compared with the negative 
control, of which the particles were assembled without PEI. (b) VMPs bearing pDTA 
(diphtheria toxin subunit A) were delivered to HeLa cells in a similar manner. Heatmap in 
cyan shows the percentage of viable cells counted per image field (n = 4) relative to untreated 
normal HeLa cells. Trypan blue exclusion assay was used to stain nonviable cells and 
exclude those from the counts.	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cells and total fluorescence as high as 20-fold over the mixture of PAP-Id(HA)/pGFP, VMPs 
assembled with PAP-Id(D137A) did not show any sign of GFP expression. Particles 
assembled without the I domains, a formulation identical to conventional PEI-based 
transfection method, overall resulted in much lower GFP expression compared with VMPs. 
Furthermore, the addition of serum almost completely abolished GFP expression induced by 
conventional PEI-based transfection (Figure 2a). 
To demonstrate ICAM-1-specific delivery of functional genes, we assembled the 
particles with a plasmid encoding a catalytic domain (subunit A) of diphtheria toxin without 
the other two domains responsible for receptor-binding and endosomal escape [45] (pDTA). 
This would limit a potent cell killing only to the transfected cells but not to the neighboring 
non-transfected cells. Cell death mediated by pDTA-encapsulating VMPs would thus 
indicate that our delivery system was able to compensate for the functions provided by the 
other two missing domains: cell binding/entry and endosomal escape. Potent cytotoxicity in 
HeLa cells was evident at similar mass ratios found to be optimal for the delivery of pGFP 
(Figure 2b). In contrast to highly efficient and ICAM-1-dependent cell killing by PAP-
Id(HA)-mediated delivery, pDTA/PEI particles in the presence of serum and the VMPs 
assembled with PAP-Id(D137A) were completely ineffective in causing cell death. 
Altogether, these assays provided evidence that Id(HA), but not PEI, was responsible for 
specific targeting of ICAM-1 and cell entry of VMPs. 
 
Inflammation-specific gene delivery to endothelial cells and monocytes/macrophages 
Major cellular culprits of inflammatory diseases [46, 47] are endothelial cells that line 
the luminal surface of blood vessels and immune cells that actively elicit immune responses. 
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Cell-surface expression of ICAM-1 is highly upregulated in the course of acute and chronic 
inflammation, which makes ICAM-1 a target for inflammatory diseases. We chose human 
dermal microvascular endothelial cells (HMEC-1) and human acute monocytic leukemia 
cells (THP-1) as representative in vitro cellular models. As a model of inflammation, HMEC-
1 and THP-1 were treated with endotoxin lipopolysaccharides (LPS) (Figure 3a) that would 
initiate nuclear factor-kappa B transcription factor-dependent inflammatory response [48] 
VMPs formulated with a fixed mass ratio of pGFP to PEI at 1:6 and varying amounts of 
targeting moiety were delivered to either normal or LPS-treated HMEC-1 (Figures 3b and c) 
and THP-1 cells (Figures 3d and e). Overall, LPS- or inflammation- dependent delivery of 
GFP gene was observed only with VMPs assembled with PAP-Id(HA), with 480% of cells 
being GFP-positive. Particles formed without the I domain showed a much lower efficiency 
of transfection independent of LPS treatment, which was largely abolished by the addition of 
serum. Notably, pGFP/PEI transfection caused cell death reaching as high as 90%, whereas 
VMPs with PAP-Id(HA) preserved the viability of both HMEC-1 and THP-1. 
One of the major advantages of using the I domain for targeted delivery is that it 
cross-reacts with murine ICAM-1 [42, 43], allowing the same targeting moiety to be used for 
preclinical animal studies. Similarly, we chose two types of cells, mouse brain microvascular 
endothelial cells (bEnd.3) and mouse leukemic monocyte macrophage cells (RAW 264.7), to 
study inflammation- specific delivery of VMPs bearing pGFP. Overall, the induction of 
ICAM-1 in murine cells in response to LPS was slower than in human cells; accordingly, we 
delivered VMPs at 48 h post-LPS treatment (Figure 4a). Similar to the effects of VMPs on 
human cells, mean fluorescence intensity and the percentage of GFP-positive cells for both 
bEnd.3 and RAW 264.7 were significantly higher in the group that were treated with LPS  
 
 113 
 
 
 
 
 
Figure 3. Inflammation-specific targeted gene delivery to human endothelial cells and 
monocyte/macrophages. (a) Timeline shows the sequence of LPS treatment, virus-particle 
delivery and measurements for human cell lines. Twenty-four hours of LPS treatment was 
required in human cells to trigger maximal ICAM-1 expression level for optimal delivery. 
(b–e) VMPs were formed with varying mass ratios of the components, pGFP, PEI and PAP-
Id, and were delivered to either normal or LPS-treated HMEC-1 and human acute monocytic 
leukemia cells (THP-1). A fixed mass ratio of 1:6 between pGFP and PEI was used for all 
cases. Mass ratios of PAP-Id(HA) was titrated to assess the effect of avidity on the efficiency  
of ICAM-1-mediated endocytosis and gene delivery in human cell lines. PAP-Id(D137A) 
was used as a negative control. (b, d) Cells were analyzed for mean fluorescence intensity 
and percentage of GFP-positive cells by flow cytometry (n = 4). (b, d) Cell viability was 
measured by MTT assay (n = 4). Data represent mean ± s.d. (c, e) Representative 
fluorescence and light microscopic images of the optimal mass ratio (pGFP:PEI:PAP-Id 
adjusted to 1:6:16) are shown. Bar = 50 µm. 
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Figure 4. Inflammation-specific targeted gene delivery to mouse endothelial cells and 
monocyte/macrophages. (a) Timeline shows the sequence of LPS treatment, virus-particle 
delivery and measurements for mouse cell lines. LPS was treated for 48 h in mouse cells to 
reach maximal ICAM-1 expression level for optimal delivery. (b–e) VMPs were formed with 
varying mass ratios of the components, pGFP, PEI and PAP-Id, and were delivered to either 
normal or LPS-treated bEnd.3 and RAW 264.7. A fixed mass ratio of 1:6 between pGFP and 
PEI was used for all cases. Mass ratios of PAP-Id(HA) was titrated to assess the effect of 
avidity on the efficiency of ICAM-1-mediated endocytosis and gene delivery in mouse cell 
lines. PAP-Id(D137A) was used as a negative control. (b, d) Cells were analyzed for mean 
fluorescence intensity and percentage of GFP-positive cells by flow cytometry (n = 4). (b, d) 
Cell viability was measured by MTT assay (n = 4). Data represent mean ± s.d. (c, e) 
Representative fluorescence and light microscopic images of the optimal mass ratio 
(pGFP:PEI:PAP-Id adjusted to 1:6:16) are shown. Scale bar = 50 µm. 
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and received VMPs formed with PAP-Id(HA) (Figures 4b–e). pGFP/PEI without added 
serum resulted in up to 90% GFP-positive in bEnd.3, irrespective of LPS treatment (Figures 
4b and c). RAW 264.7 after treatment with LPS became enlarged and autofluorescent, 
resulted in an increase in fluorescence intensity across all conditions (Figures 4d and e). 
Nonetheless, PAP-Id(HA)-mediated delivery resulted in a significant increase in fluorescence 
and as much as 20% cells were determined GFP-positive (Figures 4d and e). For LPS-treated 
RAW 264.7cells, pGFP/PEI particles delivered without serum resulted in B15% GFP-
positive cells, ascribed to nonspecific phagocytic uptake of activated macro- phages. PAP- 
Id(HA)-mediated delivery preserved cell viability, while non-specific pGFP/PEI transfection 
caused significant cell death in both the cell lines. 
 
Inflammation-specific gene delivery to primary mouse lung cells  
We also studied gene delivery to primary mouse lung cells cultured in vitro, harvested 
from a transgenic mouse strain, where exogenous Cre recombinase would excise the loxP-
flanked transcriptional STOP region and turn on GFP expression. We formed VMPs with a 
plasmid encoding Cre recombinase fused to nuclear localization signal under the CMV 
promoter. Similarly, cells were treated with LPS and received VMPs (Figure 5a), formulated 
with a fixed ratio of pCRE to PEI (1:6) and with varying amounts of PAP-Id (Figure 5b). 
PAP-Id(HA)-mediated delivery was specific to LPS-treated cells, evidenced by increased 
mean fluorescence intensity (Figures 5b and c). Normal cells treated with VMPs were as high 
as 40% GFP-positive, presumably because even a low copy number of Cre recombinase can 
excise STOP signal and induce GFP expression. PAP-Id(HA)-mediated delivery to LPS-
treated cells, however, resulted in 90% GFP-positive cells. Conventional transfection of  
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Figure 5. Inflammation-specific targeted delivery to primary mouse lung cells. (a) Timeline 
shows the sequence of treatments for VMP delivery to primary mouse lung cells in culture. 
Lung cells were harvested from a mouse strain engineered for inducible expression of GFP 
after Cre recombinase-mediated loxP-STOP-loxP excision. (b) VMPs were assembled with 
pCRE (Cre recombinase) and delivered to either normal or LPS treated primary mouse lung 
cells. A fixed mass ratio of 1:6 between pCRE and PEI was used for all cases. Mass ratios of 
PAP-Id(HA) was titrated to assess the effect of avidity on the efficiency of ICAM-1-
mediated endocytosis and gene delivery in primary lung cells. PAP-Id(D137A) was used as a 
negative control. Cells were analyzed for mean fluorescence intensity and percentage of 
GFP-positive cells by flow cytometry (n = 4). Cell viability was measured by MTT assay (n 
= 4). Data represent mean ± s.d. c) Representative fluorescence and light microscopic images 
of the optimal mass ratio (pCRE:PEI:PAP-Id adjusted to 1:6:16) are shown. Bar = 50 µm. 
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Figure 6. Systemic and inflammation-specific targeted gene delivery to the mouse lung in 
vivo. (a) Cell-surface expression of ICAM-1 in CD31- positive endothelial cells and (b) 
F4/80-positive monocyte/macrophages in the mouse lung was detected by flow cytometry 
with I domain fused to GFP (GFP-Id(HA)) (n = 4). Lungs were collected 72 h after systemic 
LPS injection for comparison of the level of ICAM-1 expression between normal and 
inflamed states. Percentage of cells in each quadrant is shown. (c–g) VMPs bearing pGFP 
was systemically applied in vivo to target inflamed mouse lung. Mass ratio of the 
components of VMPs was fixed to 1:6:16 (pGFP:PEI:PAP-Id). VMPs were injected 
intravenously via lateral tail vein route into either normal or LPS-treated mice (BALB/c). (c) 
Timeline shows the sequence of treatments, injections and data collection. (d) Lungs were 
collected and analyzed for GFP mRNA expression by quantitative PCR. Expression was 
normalized to a housekeeping gene (CYC1) and presented as relative fold difference as 
compared with PAP-Id(D137A) case (n = 4). PAP-Id(HA)-mediated delivery to LPS-treated 
group was statistically significant among all the groups. Data represent mean ± s.d. (*P < 
0.05, one-way analysis of variance followed by Tukey’s post-hoc test). (e) Flow cytometric 
histograms show GFP expression assessed by immunostaining of fixed/ permeabilized lung 
cells (n = 4). Lung cells were dual labeled for GFP and for either CD31 or F4/80 and were 
analyzed for the percentage of GFP-positive cells (black dots) within (f) CD31-positive or (g) 
F4/80-positive subset (yellow region and dotted box). FSC, forward scatter; NS, not 
significant. 
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pCRE/PEI in serum-free media resulted in a significant cytotoxicity of primary cells, 
whereas no cell death was observed with fully assembled VMPs. 
 
Inflammation-specific targeted gene delivery of VMPs in vivo  
Gene delivery has the potential to treat many diseases, which may benefit much from 
systemic and targeted treatments via intravenous routes. Cationic nonviral gene delivery 
systems without molecular targeting are severely limited due to loss of efficiency in cell 
entry, inhibited by negatively charged molecules (for example, glycosaminoglycans) in blood 
serum. We chose to study the delivery of VMPs to the lung, where endothelial cells comprise 
a large portion of tissue composition. We also confirmed that cell-surface expression of 
ICAM-1 is highly upregulated in the lungs after systemic LPS treatment. 
As for specific cell types, upregulation of ICAM-1 was observed in 450% of CD31-
positive cells (Figure 6a), which consist of mainly endothelial cells and small percentages of 
a subset of immune cells. We also found a comparable level of ICAM-1 induction in F4/80-
positive myeloid lineage macrophages, which participate critically in inflammatory diseases, 
including atherosclerosis and cancer (Figure 6b). We injected VMPs bearing pGFP via the 
lateral tail vein route, either to normal or LPS-treated mice (BALB/c) (Figure 6c). Relative 
amount of GFP mRNA expression in the lung was analyzed at 48 h post injection of VMPs 
(Figure 6d). PAP-Id(HA)-mediated delivery was specific to LPS-treated group, whereas 
pGFP/PEI particles had a lower gene transfer efficiency irrespective of the induction of 
inflammation (Figure 6d). Similarly, gene delivery by VMPs formulated with PAP-
Id(D137A) was ineffective (Figure 6d). VMP delivery for GFP expression in the lung was 
also assessed at 72 h post delivery by immunostaining of fixed/permeabilized and 
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collagenase-digested lung cells (Figure 6e). Gene delivery by VMPs with PAP-Id(HA) was 
specific to LPS-treated group, resulting in nearly 15% of the entire cell population being 
GFP-positive, while pGFP/PEI particles produced much less GFP-positive cells irrespective 
of inflammatory condition (Figure 6e). We further analyzed for the types of cells that were 
targeted by PAP-Id(HA)-mediated delivery (Figures 6f and g). Specifically, 71% of GFP-
positive cells were CD31-positive cells (Figure 6f), whereas only about 14% of GFP- 
positive cells were F4/80-positive (Figure 6g). This finding demonstrates that intravenous 
delivery of VMPs was mainly against the cellular components that are directly accessible to 
the agents in circulation and express high levels of ICAM-1 in response to LPS treatment. 
 
Discussion 
 
In this study, we have demonstrated that VMPs can be formulated by functionalizing 
PEI with a PAP for fusion to targeting moieties, allowing systemic and molecular interaction-
dependent gene delivery. With the targeting moiety derived from the integrin LFA-1, our 
VMPs were highly selective to cells with inflammation-induced overexpression of ICAM-1. 
VMPs mimicked some of the essential properties of non-enveloped viruses by possessing the 
ability to (a) package large nucleic acid molecules by PEI-mediated condensation, (b) bind 
specifically to cell-surface receptors, (c) elicit receptor-mediated endocytosis, (d) escape 
endosomal degradation (attributed to the proton sponge effect of PEI) and (e) express the 
payload gene with high efficiency. 
VMPs were far more efficient in delivering genes to cells with overexpressed ICAM-
1 than cells at basal level, which enabled inflammation-specific delivery both in vitro and in 
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vivo. This is analogous to HRVs that displayed enhanced infectivity when host cells were 
treated with inflammatory cytokines and upregulated ICAM-1 [49]. The efficiency of gene 
transfer by VMPs was also largely dependent on the coating density or avidity of PAP-Id, as 
it would influence the degree of multimeric interaction with ICAM-1 necessary for receptor-
mediated endocytosis. Furthermore, in contrast to toxicity-laden conventional transfection by 
PEI due to plasma membrane destabilization associated with non-specific internalization, 
molecular interaction-dependent uptake of VMPs produced little cytotoxicity. We speculate 
that, unlike how nonspecific uptake of densely charged cationic particles can damage cell 
membranes and cause cell death [9], viability may have been maintained as receptor-
mediated endocytosis is an active cellular process that can be regulated by cells. Greatly 
reduced toxicity with VMPs is also ascribed to the presence of PAP that counterbalances 
positive charges of PEI. 
By targeting ICAM-1, VMPs delivered genes mostly to CD31- positive cells in the 
lung, which are predominantly composed of pulmonary endothelial cells. With the current 
detection method of gene expression, we failed to observe GFP expression in other organs, 
including the liver, despite accumulation of VMPs therein. Although further work is required 
to finely control the size of VMPs and its subsequent effects on biodistribution, clearance 
rate and other pharmacokinetic parameters with the given size of VMPs (150–250nm in 
diameter), we expect that targeted cells would mainly be the ones that reside in the blood-
accessible stroma as opposed to the parenchyma. However, endothelial cells as well as 
immune cells such as monocytes/macrophages have been implicated to have critical roles in 
the pathology of inflammatory diseases, especially in the cases of atherosclerosis [47], 
psoriasis and arthritis [50]. The ability to deliver corrective genes specifically to these types 
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of cells under dysregulated inflammation should provide an immense therapeutic 
opportunity, even without the access to the parenchyma. 
Apart from the ability of viruses to efficiently deliver genes into host cells, they also 
have evolved mechanisms to self-replicate their genome, elude the immune system by 
synthesizing viral cytokine homologues and over-ride host cellular component or activity. 
Likewise, the use of more advanced genetic materials (for example, plasmids with promoters 
for improved expression or cell type-specific expression, mechanisms for self-
replication/integration or functions that can be activated under disease-associated cellular 
activities) may further improve VMPs for enhanced gene transfer efficiency, specificity and 
safety. Finally, we anticipate that simplicity and versatility of the system developed in this 
study may facilitate rapid assessments of multifaceted VMPs, formed with a range of 
different targeting moieties and payloads, and contribute to successful translation of nonviral 
vectors into the clinic. 
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CHAPTER 5 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
The major requirement for the success in cancer intervention is specific and efficient 
cancer cell targeting with minimal off-target effect. Since Paul Ehrlich suggested the concept 
of a “magic bullet” in 1960, “a drug that selectively attaches to diseased cells but is not toxic 
to healthy cells” [1, 2], a great deal of effort has been made for this direction. A wide range 
of factors can affect nanomedicine performance in cancer targeting, including but not limited 
to size, shape, clearance rate from blood, specificity, and affinity for target antigens [3-6]. 
The properties inherent to tumor itself also influence sensitivity and specificity of biologics 
in molecular imaging, such as size, tendency for non-specific uptake, vascular and lymphatic 
supplies, and permeability within the tumor [4, 7-10]. In this dissertation, I have investigated 
the influence of size and specificity on pharmacokinetics, biodistribution, and tumor 
targeting. Using six different commonly used biologics in the clinic as the study models, it 
was found that even though the highest localization into the tumor was obtained with full-
length antibody specific to tumor antigen, serum albumin and streptavidin were overall 
superior in tumor to blood ratios. Moreover, to our surprise, Fab format of antibodies, 
comparable in size to albumin and streptavidin, were much inferior in tumor detection to 
albumin and streptavidin, partly due to faster clearance of Fab from the blood. In addition, 
despite high level of localization into the tumor, neither control antibodies nor albumin and 
streptavidin were found inside cells. This perhaps partially explains why several currentl- 
approved nanomedicines using passive targeting strategy, e.g. Doxil (PEGylated liposomal 
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doxorubicin), Abraxane (albumin-based pacitaxel), and Genexol-PM (Micellar paclitaxel), 
failed to demonstrate significant benefit at the preclinical or clinical level, even though they 
have been observed to highly accumulate in tumor tissue as well as superior lower toxicity. 
In summary, our study in chapter 2 emphasizes that specific tumor detection by molecular 
targeting needs to be validated by comparing its biodistribution and targeting with that of 
control antibodies or other biologics (e.g., albumin). Furthermore, the use of biologics as a 
cytotoxic drug carrier will require specificity to tumor markers in order to achieve both 
localization and internalization to tumor cells. Utilizing information from our 
pharmacokinetics, biodistribution, and tumor targeting studies in vivo, we developed two 
different targeted delivery systems for both imaging and delivery applications. Our delivery 
systems include SPIO nanoparticles (chapter 3) and polyplex nanoparticles (chapter 4). Both 
systems implemented active targeting strategies to cancer cells as well as tumor-associated 
endothelial cells via ICAM-1. Our targeted delivery systems demonstrated preferential 
localization to tumor, inflamed vasculature, as well as systemic and subcutaneous 
inflammation. We anticipate that this work may greatly contribute to a successful translation 
of molecular imaging and therapeutic delivery systems into the clinic. 
 
Future Directions 
 
Targeted delivery systems are currently in active research areas. Several systems have 
been proposed so far. Each of them has their own pros and cons. As with others, our systems 
still need to be improved. To make targeted delivery systems safer, more efficient, and more 
applicable in clinical settings, several factors need to be taken into consideration. In this 
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dissertation, we have focused our attention to the delivery of targeted nanomedicine to 
tumors and inflammation via ICAM-1 interaction. Here are the potential factors that could 
enhance the targeting capability of our systems.  
First, our studies as well as several other studies in the field of tumor-targeting drug 
delivery utilized xenografted mouse models; the most frequently used animal models. Human 
cancer cells generally grow faster in immunocompromised mice than in humans. If a 
subcutaneously inoculated tumor in a mouse grows to 1 cm (~0.5 g) within 2–4 weeks, this 
would comparable to a ~20 cm and ~1–2 kg tumor in humans, which would take years, 
instead of weeks, to establish [11]. Because of this rapid growth, blood vessels in mouse 
tumors typically do not develop properly, and they consequently tend to be much more leaky 
than their human counterparts. This leads to such a major pitfall that the EPR effect is often 
overrated and/or misinterpreted. As a matter of fact, almost all nanomedicines, regardless of 
targeting strategies, primarily rely on EPR effect for their passive distribution through the 
tumor vasculatures and tissue for tumor localization. This might explain why some of the 
very promising nanomedicines that worked very well in mouse models, failed to demonstrate 
significant benefit at the clinical level. Apart from overestimation of the potential usefulness 
of passively targeted nanomedicine formulations, another important aspect to keep in mind is 
the heterogeneity of EPR effect, which varies substantially from tumor to tumor, as well as 
from patient to patient [10, 12]. Therefore, I envision that it would be very helpful to 
incorporate some anatomical and (patho-) physiological information of each individual tumor 
while evaluating tumor-targeting efficacy. In addition, it would be of clinical importance to 
investigate tumor-targeting efficacy of our targeted nanomedicines in different tumor models 
with diverse EPR effect levels. Focusing especially on the case of properly differentiated 
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blood vessels and densely covered with pericytes and/or smooth muscle cells would be of 
great interest and it could take more than a year to grow such tumors in size relevant to 
human cancer patients. 
The second important pitfall that could hamper the nanomedicine efficacy is tumor 
penetration ability. Upon leaving tumor blood vessels, extravasated nanoparticles need to 
penetrate into and distribute across the interstitium, to reach as many cancer cells as possible. 
Due to the high tumor cell density and the high interstitial fluid pressure, we found our 
nanoparticle accumulated heterogeneously, limited and preferably highly accumulated in 
perivascular regions. This insight strongly suggests that attempts should be made to tailor the 
size of nanomedicines to one that enables long-circulation properties, but at the same time 
also allows for proper extravasation and penetration. I reason that multistage nanoparticle 
delivery system should potentially improve the penetration and the intratumoral distribution. 
Specifically, multistage nanoparticles could offer initial benefit from their relatively large 
size to ensure prolonged circulation time. However upon extravasation, they should be 
degraded to ~10 nm-sized ‘sub-particles’ by tumor-associated proteases, such as matrix 
metalloproteinases, thereby enabling deep penetration into tumor tissue [13]. 
The last but not least, binding-site barrier phenomenon is another factor that need to 
be considered for our future targeting nanomedicine design[14]. The binding-site barrier is 
based on the notion that ligand-modified nanomedicines will bind to the first receptors they 
encounter, and therefore will not penetrate very deeply into the tumor. It could provide the 
perception that antibody with the highest affinity to the target antigen would not necessary 
result in the best therapeutic outcome, but the lower to medium affinity interaction could 
potentially be better suit for targeted delivery systems [15, 16]. In addition, specific uptake of 
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anti-ICAM/carrying nanoparticles directly correlated with nanoparticle avidity controlled by 
ligand surface density. High ligand surface density favors multivalent and avid binding of 
nanoparticles to off-target tissues with basal low expression target maker. Therefore in some 
cases reduction of ligand density may provide more selective targeting with optimal result 
[17]. Therefore, we should take into account and investigate the modulation of affinity and 
avidity of targeted delivery systems. By varying affinity and number of targeting molecules 
on the surface of nanoparticles, we could compare and optimize the delivery systems to 
provide better tumor penetration, enhance selectivity, and minimize off-target delivery into 
irrelevant tissues. 
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